Spectrum Pharmaceuticals (SPPI) 10-Q 7 May 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2020	Apr. 30, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity File Number	001-35006
Entity Registrant Name	SPECTRUM PHARMACEUTICALS INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	93-0979187
Entity Address, Address Line One	11500 South Eastern Avenue
Entity Address, Address Line Two	Suite 240
Entity Address, City or Town	Henderson
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89052
City Area Code	702
Local Phone Number	835-6300
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	SPPI
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		116,468,472
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Central Index Key	0000831547
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 70,352	$ 64,418
Marketable securities	107,441	159,455
Accounts receivable, net of allowance for credit losses of $43 and $43, respectively	435	441
Other receivables	8,789	9,558
Prepaid expenses and other assets	10,263	10,148
Total current assets	197,280	244,020
Property and equipment, net of accumulated depreciation	12,058	11,607
Other assets	3,187	4,000
Facility and equipment under lease	3,467	3,806
Total assets	215,992	263,433
Current liabilities:
Accounts payable and other accrued liabilities	49,130	54,284
Accrued payroll and benefits	4,568	7,686
Total current liabilities	53,698	61,970
Other long-term liabilities	8,526	11,070
Total liabilities	62,224	73,040
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value; 300,000,000 shares authorized; 114,774,079 and 113,299,612 issued and outstanding at March 31, 2020 and December 31, 2019, respectively	114	113
Additional paid-in capital	923,480	918,205
Accumulated other comprehensive loss	(4,827)	(3,498)
Accumulated deficit	(764,999)	(724,427)
Total stockholders’ equity	153,768	190,393
Total liabilities and stockholders’ equity	$ 215,992	$ 263,433

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 43	$ 43
Preferred stock, par value ($ per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (shares)	5,000,000	5,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value ($ per share)	$ 0.001	$ 0.001
Common stock, shares authorized (shares)	300,000,000	300,000,000
Common stock, shares issued (shares)	114,774,079	113,299,612
Common stock, shares outstanding (shares)	114,774,079	113,299,612

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenues (Note 1(b))	$ 0	$ 0
Operating costs and expenses:
Selling, general and administrative	14,794	15,952
Research and development	15,993	21,886
Total operating costs and expenses	30,787	37,838
Loss from continuing operations before other expense and income taxes	(30,787)	(37,838)
Other (expense) income:
Interest income, net	704	1,061
Other expense, net	(10,534)	(11,285)
Total other expense	(9,830)	(10,224)
Loss from continuing operations before income taxes	(40,617)	(48,062)
Benefit for income taxes from continuing operations	0	8,216
Loss from continuing operations	(40,617)	(39,846)
Income from discontinued operations, net of income taxes (Note 10)	45	20,587
Net loss	$ (40,572)	$ (19,259)
Basic and diluted loss per share:
Loss per common share from continuing operations ($ per share)	$ (0.36)	$ (0.36)
Income per common share from discontinued operations ($ per share)	0	0.19
Net loss per common share ($ per share)	$ (0.36)	$ (0.18)
Weighted average shares outstanding:
Basic (shares)	111,780,571	109,552,602
Diluted (shares)	111,780,571	109,552,602

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (40,572)	$ (19,259)
Other comprehensive loss:
Unrealized loss on available-for-sale securities, net of income tax expense of $0 and $0 for the three months ended March 31, 2020 and 2019, respectively.	(914)	0
Foreign currency translation adjustments	(415)	(390)
Other comprehensive loss	(1,329)	(390)
Total comprehensive loss	$ (41,901)	$ (19,649)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive (Loss) Income (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Unrealized loss on available-for-sale securities, tax	$ 0	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning Balance, (shares) at Dec. 31, 2018		110,525,141
Beginning Balance at Dec. 31, 2018	$ 271,410	$ 110	$ 886,740	$ (3,702)	$ (611,738)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(19,259)				(19,259)
Other comprehensive loss, net	(390)			(390)
Recognition of stock-based compensation expense	7,481		7,481
Issuance of common stock to 401(k) plan for employees (shares)		47,347
Issuance of common stock to 401(k) plan for employees	519		519
Issuance of common stock upon exercise of stock options (shares)		146,785
Issuance of common stock upon exercise of stock options	831			831
Restricted stock award grants, net of forfeitures (shares)		259,539
Restricted stock award grants, net of forfeitures	1	$ 1
Issuance of common stock upon vesting of restricted stock units (shares)		233,760
Issuance of common stock upon vesting of restricted stock units	0
Ending Balance, (shares) at Mar. 31, 2019		111,212,572
Ending Balance at Mar. 31, 2019	260,593	$ 111	895,571	(4,092)	(630,997)
Beginning Balance, (shares) at Dec. 31, 2019		113,299,612
Beginning Balance at Dec. 31, 2019	190,393	$ 113	918,205	(3,498)	(724,427)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(40,572)				(40,572)
Other comprehensive loss, net	(1,329)			(1,329)
Recognition of stock-based compensation expense	5,010		5,010
Issuance of common stock to 401(k) plan for employees (shares)		96,959
Issuance of common stock to 401(k) plan for employees	265		265
Restricted stock award grants, net of forfeitures (shares)		1,377,508
Restricted stock award grants, net of forfeitures	1	$ 1
Ending Balance, (shares) at Mar. 31, 2020		114,774,079
Ending Balance at Mar. 31, 2020	$ 153,768	$ 114	$ 923,480	$ (4,827)	$ (764,999)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash Flows From Operating Activities:
Loss from continuing operations	$ (40,617)	$ (39,846)
Income from discontinued operations, net of income taxes (Note 10)	45	20,587
Net loss	(40,572)	(19,259)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	140	1,331
Stock-based compensation (Note 4)	5,275	8,000
Recognized gain on Commercial Product Portfolio Transaction (Note 10)	0	(33,644)
Amortization of operating leases (Note 8(a))	381	509
Amortization of discount on investments in debt securities, recorded to interest income (Note 3(a))	(29)	0
Realized gain on mutual funds	(189)	0
Unrealized loss on CASI stock holdings (Note 3(a) and Note 7)	10,238	12,183
Unrealized gain from transactions denominated in foreign currency	(22)	(1)
Change in deferred tax liabilities	0	(1,469)
Change in fair value of contingent consideration (Note 8(b))	0	1,478
Changes in operating assets and liabilities:
Accounts receivable, net	0	14,914
Other receivables	762	(3,776)
Inventories	0	(2,037)
Prepaid expenses and other assets	(960)	512
Other assets	823	(980)
Accounts payable and other accrued liabilities	(3,919)	(14,151)
Accrued payroll and benefits	(3,118)	(4,685)
FOLOTYN development liability	0	(4)
Other long-term liabilities	(2,153)	1,024
Net cash used in operating activities	(33,343)	(40,055)
Cash Flows From Investing Activities:
Proceeds from Commercial Product Portfolio Transaction (Note 1(b))	0	158,765
Proceeds from maturities of marketable securities	50,133	0
Proceeds from sale of mutual funds	833	0
Purchases of investment securities available-for-sale (Note 3(a))	(8,998)	0
Purchases of mutual funds	(1,210)	0
Purchases of property and equipment (Note 3(b))	(1,395)	(314)
Net cash provided by investing activities	39,363	158,451
Cash Flows From Financing Activities:
Proceeds from employees for exercises of stock options	0	831
Net cash provided by financing activities	0	831
Effect of exchange rates on cash, cash equivalents and restricted cash	(86)	(55)
Net increase in cash, cash equivalents and restricted cash	5,934	119,172
Cash, cash equivalents and restricted cash—beginning of period	64,418	157,480
Cash, cash equivalents and restricted cash—end of period	70,352	276,652
Supplemental disclosure of cash flow information:
Cash paid for facility and equipment under operating leases	593	471
Cash paid for income taxes	0	33
Noncash investing activities:
Additions of property and equipment that remain in accounts payable and other accrued liabilities (Note 3(b))	$ 2,772	$ 0

Description of Business, Basis

Description of Business, Basis of Presentation, and Operating Segment	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business, Basis of Presentation, and Operating Segment	DESCRIPTION OF BUSINESS, BASIS OF PRESENTATION, AND OPERATING SEGMENT (a) Description of Business Spectrum Pharmaceuticals, Inc. (“Spectrum”, the “Company”, “we”, “our”, or “us”) is a biopharma company, with a primary strategy comprised of acquiring, developing, and commercializing novel and targeted oncology therapies. Our in-house development organization includes clinical development, regulatory, quality and data management. We plan to build out our commercial and marketing capabilities in the second half of 2020 to prepare for the launch of ROLONTIS. We have three drugs in development: • ROLONTIS, a novel long-acting granulocyte colony-stimulating (“G-CSF”) for chemotherapy-induced neutropenia which has been filed with the FDA and has a Prescription Drug User Fee Act (“PDUFA”) date of October 24, 2020; • Poziotinib, a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer (“NSCLC”) tumors with various mutations; and • Anti-CD20-IFNα, an interferon fusion molecule directed against CD20 that is in Phase 1 development for treating relapsed or refractory non-Hodgkin’s lymphoma (“NHL”) patients (including diffuse large B-cell lymphoma). Our business strategy is the development of our late-stage assets through commercialization and the sourcing of additional assets that are synergistic with our existing portfolio (through purchase acquisitions, in-licensing transactions, or co-development and marketing arrangements). (b) Basis of Presentation Interim Financial Statements The interim financial data for the three months ended March 31, 2020 and 2019 is unaudited and is not necessarily indicative of our operating results for a full year. In the opinion of our management, the interim data includes normal and recurring adjustments necessary for a fair presentation of our financial results for the three months ended March 31, 2020 and 2019. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to the Securities and Exchange Commission (“SEC”) rules and regulations relating to interim financial statements. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and Notes thereto included within our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (filed with the SEC on March 2, 2020). Discontinued Operations - Sale of our Commercial Product Portfolio On March 1, 2019, we completed the sale of our seven then-commercialized drugs, including FUSILEV, KHAPZORY, FOLOTYN, ZEVALIN , MARQIBO, BELEODAQ, and EVOMELA (the “Commercial Product Portfolio”) to Acrotech Biopharma LLC (“Acrotech”) (the “Commercial Product Portfolio Transaction”). Upon closing we received $158.8 million in an upfront cash payment (of which $4 million was held in escrow until November 2019). We are also entitled to receive up to an aggregate of $140 million upon Acrotech's future achievement of certain regulatory milestones (totaling $40 million) and sales-based milestones (totaling $100 million) relating to the Commercial Product Portfolio. These Condensed Consolidated Financial Statements reflect the corresponding revenue-deriving activities and allocable expenses of this commercial business within “discontinued operations” - see Note 10 . We have presented our face financial statements in general conformity with our historical format, even where presented values are $-0- within continuing operations due to required discontinued operations classification for all periods presented. We believe this format provides increased clarity and comparability with our previously filed financial statements, as well as our expectation that these financial statement captions and associated footnote disclosures will remain relevant to our future business activities. Principles of Consolidation The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with GAAP and with the rules and regulations of the SEC. These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions among these legal entities have been eliminated in consolidation. In May 2019, we dissolved Spectrum Pharma Canada Inc., previously consolidated as a “variable interest entity” (as defined under applicable GAAP). (c) Operating Segment We operate one reportable operating segment that is focused exclusively on developing (and eventually marketing) oncology and hematology drug products. For the three months ended March 31, 2020 and 2019, all of our revenue and operating costs and expenses were solely attributable to these activities (and as applicable, classified as “discontinued” within the accompanying Condensed Consolidated Statements of Operations - see Note 10 ). All of our assets are held in the U.S, except for cash held in certain foreign bank accounts.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Use of Estimates	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Use of Estimates	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES The preparation of financial statements in conformity with GAAP requires our management to make informed estimates and assumptions that affect our reported amounts of assets, liabilities, revenues, and expenses. These amounts may materially differ from the amounts ultimately realized and reported due to the inherent uncertainty of any estimate or assumption. On an on-going basis, our management evaluates (as applicable) its most critical estimates and assumptions, including those related to: (i) gross-to-net revenue adjustments; (ii) the timing of revenue recognition; (iii) the collectability of customer accounts; (iv) whether the cost of our inventories can be recovered; (v) the realization of our tax assets and estimates of our tax liabilities; (vi) the fair value of our investments; (vii) the valuation of our stock options and the periodic expense recognition of stock-based compensation; and (viii) the potential outcome of our ongoing or threatened litigation. Our accounting policies and estimates that most significantly impact the presented amounts within these Condensed Consolidated Financial Statements are further described below: (i) Revenue Recognition On March 1, 2019, we completed the Commercial Product Portfolio Transaction -- see Note 1(b) . In accordance with applicable GAAP ( ASC 205-20, Presentation of Financial Statements ), the revenue-deriving activities of our sold commercial operation are separately classified as “discontinued” for all periods presented within the accompanying Condensed Consolidated Statements of Operations -- see Note 10 . Required Elements of Our Revenue Recognition : Revenue from our (a) product sales, (b) out-license arrangements, and (c) service arrangements is recognized under Accounting Standards Update (“ ASU ”) No. 2014-09 , Revenue from Contracts with Customers ( “Topic 606” ) in a manner that reasonably reflects the delivery of our goods and/or services to customers in return for expected consideration and includes the following elements: (1) we ensure that we have an executed contract(s) with our customer that we believe is legally enforceable; (2) we identify the “performance obligations” in the respective contract; (3) we determine the “transaction price” for each performance obligation in the respective contract; (4) we allocate the transaction price to each performance obligation; and (5) we recognize revenue only when we satisfy each performance obligation. These five elements, as applied to each of our revenue categories, are summarized below: (a) Product Sales : We sell our products to pharmaceutical wholesalers/distributors or to our product licensees (i.e., our customers). Our wholesalers/distributors in turn sell our products directly to clinics, hospitals, and private oncology-based practices. Revenue from our product sales is recognized as physical delivery of product occurs (when our customer obtains control of the product), in return for agreed-upon consideration. Our gross product sales (i.e., delivered units multiplied by the contractual price per unit) are reduced by our corresponding gross-to-net (“GTN”) estimates using the “expected value” method, resulting in reported “product sales, net” that reflects the amount we ultimately expect to realize in net cash proceeds, taking into account our current period gross sales and related cash receipts, and the subsequent cash disbursements on these sales that we estimate for the various GTN categories discussed below. These estimates are based upon information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the period), in combination with management’s informed judgments. Due to the inherent uncertainty of these estimates, the actual amount incurred (of some, or all) of product returns, government chargebacks, prompt pay discounts, commercial rebates, Medicaid rebates, and distribution, data, and GPO administrative fees may be materially above or below the amount estimated, then requiring prospective adjustments to our reported net product sales. These GTN estimate categories (that comprise our GTN liabilities within Note 3(g) ) are each discussed below: Product Returns Allowances : Our customers are contractually permitted to return certain purchased products within the contractual allowable time before/after its applicable expiration date. Returns outside of this aforementioned criteria are not customarily allowed. We estimate expected product returns using our historical return rates. Returned product is typically destroyed since substantially all are due to its imminent expiry and cannot be resold. Government Chargebacks : Our products are subject to pricing limits under certain federal government programs (e.g., Medicare and 340B Drug Pricing Program). Qualifying entities (i.e., end-users) purchase products from our customers at their qualifying discounted price. The chargeback amount we incur represents the difference between our contractual sales price to our customer, and the end-user’s applicable discounted purchase price under the government program. There may be significant lag time between our reported net product sales and our receipt of the corresponding government chargeback claims from our customers. Prompt Pay Discounts : Discounts for prompt payment are estimated at the time of sale, based on our eligible customers’ prompt payment history and the contractual discount percentage. Commercial Rebates : Commercial rebates are based on (i) our estimates of end-user purchases through a group purchasing organization (“GPO”), (ii) the corresponding contractual rebate percentage tier we expect each GPO to achieve, and (iii) our estimates of the impact of any prospective rebate program changes made by us. Medicaid Rebates : Our products are subject to state government-managed Medicaid programs, whereby rebates are issued to participating state governments. These rebates arise when a patient treated with our product is covered under Medicaid, resulting in a discounted price for our product under the applicable Medicaid program. Our Medicaid rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time lag in our receiving rebate notices from each state (generally several months or longer after our sale is recognized). Our estimates are based on our historical claim levels by state, as supplemented by management’s judgment. Distribution, Data, and GPO Administrative Fees : Distribution, data, and GPO administrative fees are paid to authorized wholesalers/distributors of our products for various commercial services including: contract administration, inventory management, delivery of end-user sales data, and product returns processing. These fees are based on a contractually-determined percentage of our applicable sales. (b) License Fees : Our out-license arrangements allow licensees to market our product(s) in certain territories for a specific term (representing the out-license of “functional intellectual property”). These arrangements may include one or more of the following forms of consideration: (i) upfront license fees, (ii) sales royalties, (iii) sales milestone-achievement fees, and (iv) regulatory milestone-achievement fees. We recognize revenue for each based on the contractual terms that establish our right to collect payment once the performance obligation is achieved, as follows: (1) Upfront License Fees: We determine whether upfront license fees are earned at the time of contract execution (i.e., when rights transfer to the customer) or over the actual (or implied) contractual period of the out-license. As part of this determination, we evaluate whether we have any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer. Our customers’ “distinct” rights to licensed “functional intellectual property” at the time of contract execution results in concurrent revenue recognition of all upfront license fees (assuming that there are no other performance obligations at contract execution that are inseparable from this license transfer). (2) Royalties : Under the “sales-or-usage-based royalty exception” we recognize revenue in the same period that our licensees complete product sales in their territory for which we are contractually entitled to a percentage-based royalty receipt. (3) Sales Milestones : Under the “sales-or-usage-based royalty exception” we recognize revenue in full within the period that our licensees achieve annual or aggregate product sales levels in their territories for which we are contractually entitled to a specified lump-sum receipt. (4) Regulatory Milestones : Under the terms of the respective out-license, regulatory achievements may either be our responsibility, or that of our licensee. • When our licensee is responsible for the achievement of the regulatory milestone, we recognize revenue in full (for the contractual amount due from our licensee) in the period that the approval occurs (i.e., when the “performance obligation” is satisfied by our customer) under the “most likely amount” method. This revenue recognition remains “constrained” (i.e., not recognized) until regulatory approval occurs, given its inherent uncertainty and the requirement of a significant revenue reversal not being probable if achievement does not occur. At each reporting period, we re-evaluate the probability of milestone achievement and the associated revenue constraint; any resulting adjustments would be recorded on a cumulative catch-up basis, thus reflected in our financial statements in the period of adjustment. • When we are responsible for the achievement of a regulatory milestone, the “relative selling price method” is applied for purposes of allocating the transaction price to our performance obligations. In such case, we consider (i) the extent of our effort to achieve the milestone and/or the enhancement of the value of the delivered item(s) as a result of milestone achievement and (ii) if the milestone payment is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement. We have historically assessed the contractual value of these milestones upon their achievement to be identical to the allocation of value of our performance obligations and thus representing the “transaction price” for each milestone at contract inception. We recognize this revenue in the period that the regulatory approval occurs (i.e., when we complete the “performance obligation”) under the “most likely amount” method, and revenue recognition is otherwise “constrained” until regulatory approval occurs, given its inherent uncertainty and the requirement of a significant revenue reversal not being probable if achievement does not occur. At each reporting period, we re-evaluate the probability of milestone achievement and the associated revenue constraint; any resulting adjustments would be recorded on a cumulative catch-up basis, thus reflected in our financial statements in the period of adjustment. (c) Service Revenue : We receive fees under certain arrangements for (i) sales and marketing services, (ii) supply chain services, (iii) research and development services, and (iv) clinical trial management services. Our rights to receive payment for these services may be established by (1) a fixed-fee schedule that covers the term of the arrangement, so long as we meet ongoing performance obligations, (2) our completion of product delivery in our capacity as a procurement agent, (3) the successful completion of a phase of drug development, (4) favorable results from a clinical trial, and/or (5) regulatory approval events. We consider whether revenue associated with these service arrangements is reportable each period, based on our completed services or deliverables (i.e., satisfied “performance obligations”) during the reporting period, and the terms of the arrangement that contractually result in fixed payments due to us. The promised service(s) within these arrangements are distinct and explicitly stated within each contract, and our customer benefits from the separable service(s) delivery/completion. Further, the nature of the promise to our customer as stated within the respective contract is to deliver each named service individually (not a transfer of combined items to which the promised goods or services are inputs), and thus are separable for revenue recognition. (ii) Cash and Cash Equivalents Cash and cash equivalents consist of bank deposits and highly liquid investments with maturities of three months or less from the purchase date. (iii) Marketable Securities Marketable securities consist of our holdings in equity securities, mutual funds, bank certificates of deposit (“Bank CDs”), government-related debt securities, and corporate debt securities. Since we classify these investments as “available-for-sale” any (1) realized gains (losses) or (2) unrealized gains (losses) on these securities are respectively recognized in (1) “other expense, net” on the accompanying Condensed Consolidated Statements of Operations, or (2) depending on the nature of the marketable securities recognized in “accumulated other comprehensive loss” as a separate component of stockholder’s equity on the accompanying Condensed Consolidated Statements of Stockholders’ Equity, or in “other expense, net” on the accompanying Condensed Consolidated Statements of Operations. (iv) Accounts Receivable Our accounts receivable, net of allowance for credit losses are derived from our product sales and license fees, and do not bear interest. The allowance for credit losses is management’s best estimate of the amount of expected credit losses in our existing accounts receivable and any anticipated discounts. The allowance for credit losses is adjusted each period through earnings to reflect expected credit losses over the remaining life of the asset. Account balances are written off against the allowance after appropriate collection efforts are exhausted. In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13 ("ASU 2016-13") "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" , which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This new ASU replaces the existing incurred loss impairment model with a current expected credit loss model (“CECL”), which requires the use of forward-looking information to calculate credit loss estimates. The new CECL model requires recognition of credit losses for loans and other receivables at the time the financial asset is originated or acquired, in which the expected credit losses are adjusted each period for changes in expected lifetime credit losses. The new standard also applies to receivables arising from revenue transactions such as contract assets and accounts receivables and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. We adopted ASU 2016-13 as of January 1, 2020, which had no material effect on our accompanying Condensed Consolidated Financial Statements. (v) Property and Equipment Our property and equipment is stated at historical cost, and is depreciated on a straight-line basis over an estimated useful life that corresponds with its designated asset category. We evaluate the recoverability of “long-lived assets” (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset’s carrying amount may not be recoverable through our on-going operations. (vi) Stock-Based Compensation Stock-based compensation expense for equity awards granted to our employees and members of our Board of Directors is recognized on a straight-line basis over each award’s vesting period. Recognized compensation expense is net of an estimated forfeiture rate, representing the percentage of awards that are expected to be forfeited prior to vesting, though is ultimately adjusted for actual forfeitures. We use the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) that have service conditions for vesting. We use the Monte Carlo valuation model to value equity awards (as of the date of grant) that have combined market conditions and service conditions for vesting. The recognition of stock-based compensation expense and the initial calculation of stock option fair value requires uncertain assumptions, including (a) the pre-vesting forfeiture rate of the award, (b) the expected term that the stock option will remain outstanding, (c) our stock price volatility over the expected term (and that of our designated peer group with respect to certain market-based awards), and (d) the prevailing risk-free interest rate for the period matching the expected term. With regard to (a)-(d) above: we estimate forfeiture rates based on our employees’ overall forfeiture history, which we believe will be representative of future results. We estimate the expected term of stock options granted based on our employees’ historical exercise patterns, which we believe will be representative of their future behavior. We estimate the volatility of our common stock on the date of grant based on the historical volatility of our common stock for a look-back period that corresponds with the expected term. We estimate the risk-free interest rate based upon the U.S. Department of the Treasury yields in effect at award grant, for a period equaling the expected term of the stock option. (vii) Basic and Diluted Net Loss per Share We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period. (viii) Income Taxes Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We have recorded a valuation allowance to reduce our deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when we were to determine that our deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase our net income in the period that such determination was made. In the event that we are assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included in “benefit for income taxes from continuing operations” within the accompanying Condensed Consolidated Statements of Operations for the period in which we received the notice. (ix) Research and Development Costs Our research and development costs are expensed as incurred (see Note 8(c) ) or as certain milestone payments become contractually due to our licensors, as triggered by the achievement of clinical or regulatory events. (x) Fair Value Measurements We determine measurement-date fair value based on the proceeds that would be received through the sale of the asset, or that we would pay to settle or transfer the liability, in an orderly transaction between market participants. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date. Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.

Balance Sheet Account Detail

Balance Sheet Account Detail	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Account Detail	BALANCE SHEET ACCOUNT DETAIL The composition of selected financial statement captions that comprise the accompanying Condensed Consolidated Balance Sheets are summarized below: (a) Cash and Cash Equivalents and Marketable Securities As of March 31, 2020 and December 31, 2019, our “cash and cash equivalents” were held with major financial institutions. As of March 31, 2020 and December 31, 2019, our “marketable securities” include our equity holdings in CASI Pharmaceuticals, Inc. (“CASI”), mutual funds, government-related debt securities, corporate debt securities, and bank certificates of deposits (“bank CDs”). We maintain cash balances with select financial institutions. The Federal Deposit Insurance Corporation (FDIC) and other third parties insure a fraction of these deposits. Accordingly, these cash deposits are not insured against the possibility of a substantial or complete loss of principal and are inherently subject to the credit risk of the corresponding financial institution. Our investment policy requires that purchased investments may only be in highly-rated and liquid financial instruments and limits our holdings of any single issuer (excluding any debt or equity securities that may be received from our strategic partners in connection with an out-license arrangements, as discussed in Note 7 ). The carrying amount of our equity securities, money market funds, and Bank CDs approximates their fair value (utilizing “ Level 1” or “ Level 2” inputs – see Note 2(x) ) because of our ability to immediately convert these instruments into cash with minimal expected change in value. As of March 31, 2020, our held securities that remain in an unrealized loss position for less than one year were insignificant and are presented in the table below. The following is a summary of our presented composition of “cash and cash equivalents” and “marketable securities”: Historical or Amortized Cost Foreign Currency Translation Unrealized Cash and Cash Marketable Securities March 31, 2020 Equity securities (see Note 7 ) $ 6,310 $ (2,789) $ 16,976 $ — $ 20,497 $ — $ 20,497 Money market funds 54,282 — — — 54,282 54,282 — Government-related debt securities* 50,113 — 324 — 50,437 10,000 40,437 Corporate debt securities* 33,888 — 15 (159) 33,744 — 33,744 Bank deposits 6,070 — — — $ 6,070 6,070 — Mutual funds 4,941 — — (298) 4,643 — 4,643 Bank CDs 8,088 — 32 — 8,120 — 8,120 Total cash and cash equivalents and marketable securities $ 163,692 $ (2,789) $ 17,347 $ (457) $ 177,793 $ 70,352 $ 107,441 December 31, 2019 Equity securities (see Note 7 ) $ 6,310 $ (2,477) $ 27,214 $ — $ 31,047 $ — $ 31,047 Money market funds 54,199 — — — 54,199 54,199 — Government-related debt securities* 62,617 — 19 (10) 62,626 — 62,626 Corporate debt securities* 58,235 — 38 (25) 58,248 5,000 53,248 Bank deposits 5,219 — — — 5,219 5,219 — Mutual funds 4,375 — 783 — 5,158 — 5,158 Bank CDs 7,354 — 22 — 7,376 — 7,376 Total cash and cash equivalents and marketable securities $ 198,309 $ (2,477) $ 28,076 $ (35) $ 223,873 $ 64,418 $ 159,455 * Beginning in the second quarter of 2019, we purchased certain government-related and corporate debt securities. We have classified these as “available-for-sale” since we may redeem or sell these investments before their stated maturity to fund our operations. Under the requirements of ASC 320, Investments - Debt and Equity Securities: (i) we recorded these securities at initial “book value” and then amortize, through maturity, the determined “discount” or “premium” within “interest income” on the accompanying Condensed Consolidated Statements of Operations, and (ii) we recognize the “unrealized gains (loss)” of these securities (i.e., fair value versus amortized book value) as a separate component of “other comprehensive loss” on the accompanying Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2020. (b) Property and Equipment, net of Accumulated Depreciation “Property and equipment, net of accumulated depreciation” consists of the following: March 31, 2020 December 31, 2019 Manufacturing equipment* $ 10,815 $ 10,355 Computer hardware and software 3,734 3,606 Laboratory equipment 36 36 Leasehold improvements 3,374 3,374 Office furniture 248 248 Property and equipment, at cost 18,207 17,619 (Less): Accumulated depreciation (6,149) (6,012) Property and equipment, net of accumulated depreciation $ 12,058 $ 11,607 * This account is comprised of our owned ROLONTIS production equipment on location at our contract manufacturer. This equipment has alternative future use for the general production of various biologic agents. Accordingly, we have capitalized these purchases, rather than recording it as “research and development” expense in full, despite its current designation for the manufacture of pre-FDA approved product. The majority of this manufacturing equipment was not in use and therefore not being depreciated as of March 31, 2020. Depreciation for installed and ready-for-use equipment is recorded to “research and development” expense prior to FDA approval and will be prospectively recorded to “cost of sales” upon FDA approval of ROLONTIS. Depreciation expense (included within “total operating costs and expenses” in the accompanying Condensed Consolidated Statements of Operations) for the three months ended March 31, 2020 and 2019 was $0.1 million and $0.1 million, respectively. (c) Prepaid Expenses and Other Assets “Prepaid expenses and other assets” consists of the following: March 31, 2020 December 31, 2019 Vendor deposits $ 9,285 $ 8,740 Prepaid insurance 978 1,408 Prepaid expenses and other assets $ 10,263 $ 10,148 (d) Other Receivables “Other receivables” consists of the following: March 31, 2020 December 31, 2019 Insurance receivable* $ 3,337 $ 4,015 CASI other receivables 2,135 2,393 Other miscellaneous receivables 1,385 1,490 Income tax receivable - current portion 1,306 973 Interest receivable from marketable securities (see Note 3(a) ) 497 561 Reimbursements due from development partners for incurred research and development expenses 129 126 Other receivables $ 8,789 $ 9,558 * This insurance receivable balance represents our incurred legal fees and pending and completed settlements that are expected to be reimbursed by our insurance carriers. (e) Other Assets “Other assets” consists of the following: March 31, 2020 December 31, 2019 Key employee life insurance – cash surrender value (associated with deferred compensation plan - see Note 6 ) $ 3,073 $ 3,547 Income tax receivable - non-current portion* — 334 Research & development supplies and other 114 119 Other assets $ 3,187 $ 4,000 * This value was moved to “other receivables” within “total current assets” as the “Coronavirus Aid, Relief and Economic Security (CARES) Act” now allows the immediate refund of alternative minimum tax payments. Previously this amount was expected to be collected over several years (see Note 9 ). (f) Facility and Equipment Under Lease “Facility and equipment under lease” consists of the following : March 31, 2020 December 31, 2019 Office and research facilities $ 3,077 $ 3,391 Office equipment 390 415 Facility and equipment under lease $ 3,467 $ 3,806 (g) Accounts Payable and Other Accrued Liabilities “Accounts payable and other accrued liabilities” consists of the following : March 31, 2020 December 31, 2019 Trade accounts payable and other $ 26,937 $ 32,012 Lease liability - current portion 1,725 1,683 Accrued commercial/Medicaid rebates 2,870 2,925 Accrued product royalty due to licensors — 66 Allowance for product returns 4,714 4,714 Accrued data and distribution fees 768 768 Accrued GPO administrative fees 6 6 Accrued inventory management fees 364 364 Allowance for government chargebacks 11,746 11,746 Accounts payable and other accrued liabilities $ 49,130 $ 54,284 Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for our categories of GTN estimates (see Note 2(i) ) were as follows: Commercial/Medicaid Rebates and Government Chargebacks* Distribution, Data, Inventory and Product Return Allowances Balance as of December 31, 2018 $ 22,952 $ 3,932 $ 5,171 Add: GTN accruals recorded for product sales 7,702 1,209 167 (Less): Payments made and credits against GTN accruals (15,983) (4,003) (624) Balance as of December 31, 2019 $ 14,671 $ 1,138 $ 4,714 Add: GTN accruals recorded for product sales — — — (Less): Payments made and credits against GTN accruals (55) — — Balance as of March 31, 2020 $ 14,616 $ 1,138 $ 4,714 (h) Other Long-Term Liabilities “Other long-term liabilities” consists of the following: March 31, 2020 December 31, 2019 Deferred compensation liability ( Note 8(f) ) $ 6,444 $ 8,597 Lease liability - non-current portion ( Note 8(a) ) 1,981 2,372 Other tax liabilities 101 101 Other long-term liabilities $ 8,526 $ 11,070

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	STOCK-BASED COMPENSATIONWe report our stock-based compensation expense (inclusive of our incentive stock plan, employee stock purchase plan, and 401(k) contribution matching program) in the accompanying Condensed Consolidated Statements of Operations, based on the assigned department of the recipient. Stock-based compensation expense, included within “total operating costs and expenses” for the three months ended March 31, 2020 and 2019, was as follows: Three Months Ended 2020 2019 Selling, general and administrative $ 3,877 $ 3,626 Research and development 1,398 969 Total stock-based compensation* $ 5,275 $ 4,595

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	NET LOSS PER SHARE Net loss per share was computed by dividing net loss by the weighted average number of common shares outstanding for the three months ended March 31, 2020 and 2019: Three Months Ended 2020 2019 Weighted average shares outstanding - basic and diluted 111,780,571 109,552,602 Net loss $ (40,572) $ (19,259) Net loss per share – basic and diluted $ (0.36) $ (0.18)

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The table below summarizes certain asset and liability fair values that are included within our accompanying Condensed Consolidated Balance Sheets, and their designations among the three fair value measurement categories (see Note 2(x)) : March 31, 2020 Level 1 Level 2 Level 3 Total Assets: Government-related debt securities $ 35,411 $ 15,026 $ — $ 50,437 Corporate debt securities — 33,744 — 33,744 Money market funds 54,282 — — 54,282 Equity securities ( Note 7 ) 20,497 — — 20,497 Bank CDs — 8,120 — 8,120 Mutual funds 4,643 9 — 4,652 Key employee life insurance, cash surrender value - Note 3(e) ) — 3,073 — 3,073 * $ 114,833 $ 59,972 $ — $ 174,805 Liabilities: Deferred executive compensation liability ( Note 8(f) ) $ — $ 7,447 $ — $ 7,447 * $ — $ 7,447 $ — $ 7,447 December 31, 2019 Level 1 Level 2 Level 3 Total Assets: Government-related debt securities $ 47,636 $ 14,990 $ — $ 62,626 Corporate debt securities — 58,248 — 58,248 Money market funds 54,199 — — 54,199 Equity securities ( Note 7 ) 31,047 — — 31,047 Bank CDs — 7,376 — 7,376 Mutual funds 5,158 11 — 5,169 Key employee life insurance, cash surrender value - Note 3(e) ) — 3,547 — 3,547 * $ 138,040 $ 84,172 $ — $ 222,212 Liabilities: Deferred executive compensation liability ( Note 8(f) ) $ — $ 8,746 $ — $ 8,746 * $ — $ 8,746 $ — $ 8,746 * The reported amount of “key employee life insurance, cash surrender value” is based on the stated cash surrender value of life insurance policies of named current and former employees at each period-end. The reported amount of “deferred executive compensation liability” is based on the period-end market value of mutual fund investments selected by employee participants of the deferred compensation plan. We did not have any transfers between “Level 1” and “Level 2” (see Note 2(x) ) measurement categories for any periods presented.

Casi Holdings and Evomela Suppl

Casi Holdings and Evomela Supply Contract	3 Months Ended
	Mar. 31, 2020
Other Commitments [Abstract]
Casi Holdings and Evomela Supply Contract	CASI HOLDINGS AND EVOMELA SUPPLY CONTRACT Overview of CASI Transaction In 2014, we executed three perpetual out-license agreements for our former products ZEVALIN, MARQIBO, and EVOMELA (“CASI Out-Licensed Products”) with CASI, a publicly-traded biopharmaceutical company (NASDAQ: CASI) with a primary focus on the China market (collectively, the “CASI Out-License”). Under the CASI Out-License, we received CASI common stock and a secured promissory note and CASI gained the exclusive rights to distribute the CASI Out-Licensed Products in greater China (which includes Taiwan, Hong Kong, and Macau). In March 2019, we completed the Commercial Product Portfolio Transaction (see Note 1(b) ) and substantially all of the contractual rights and obligations associated with these products, including the CASI Out-License, were transferred to Acrotech at closing. However, on an interim basis we retained our original supply agreement with CASI for EVOMELA. Corresponding revenue for shipped product has been recognized within discontinued operations “product sales, net” (see Note 10 ). Given our fulfillment of this order in October 2019, this arrangement was complete as of December 31, 2019. Our Ownership in CASI at March 31, 2020 Under certain conditions that expired in December 2017, we exercised our rights during 2016 and 2017 to purchase additional shares of CASI common stock at par value in order to maintain our post-investment ownership percentage. Our aggregate holding of 10.0 million CASI common shares as of March 31, 2020 represented an approximate 10.0% ownership with a fair market value of $20.5 million (see Note 3(a) ) .

Financial Commitments & Conting

Financial Commitments & Contingencies and Key License Agreements	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Financial Commitments & Contingencies and Key License Agreements	FINANCIAL COMMITMENTS & CONTINGENCIES AND KEY LICENSE AGREEMENTS (a) Facility and Equipment Leases Overview In the ordinary course of our business, we enter into leases with unaffiliated parties for the use of (i) office and research facilities and (ii) office equipment. Our current leases have remaining terms ranging from less than one year to four years and none include any residual value guarantees, restrictive covenants, term extensions, or early-termination options. We lease our principal executive office in Henderson, Nevada under a non-cancelable operating lease expiring October 31, 2021. We also lease our research and development facility in Irvine, California under a non-cancelable operating lease expiring July 31, 2022, in addition to other administrative office leases. We recognize lease expense on a straight-line basis over the expected term of these operating leases, as reported within “selling, general and administrative” expense on the accompanying Condensed Consolidated Statements of Operations. Our facility leases have minimum annual rents, payable monthly, and some carry fixed annual rent increases. Under some of these arrangements, real estate taxes, insurance, certain operating expenses, and common area maintenance are reimbursable to the lessor. These amounts are expensed as incurred, as they are variable in nature and therefore excluded from the measurement of our reported lease asset and liability discussed below. During the three months ended March 31, 2020 and 2019, we had no sublease arrangements with us as lessor. For the three months ended March 31, 2020 and 2019, our facility and equipment lease expense aggregated $0.6 million and $0.6 million, respectively. This reported asset and liability, respectively, represents (i) the economic benefit of our use of leased facilities and equipment and (ii) the present-value of our contractual minimum lease payments, applying our estimated incremental borrowing rate as of the lease commencement date (since an implicit interest rate is not readily determinable in any of our leases). Upon adoption, we recorded $4.2 million to our January 1, 2019 balance sheet for both (i) our right-of-use asset within “facility and equipment under lease” and (ii) our lease liability within “accounts payable and other accrued liabilities” and “other long-term liabilities.” The recorded asset and liability associated with each lease is amortized over the respective lease term using the “effective interest rate” method. As of March 31, 2020, we recognized $5.3 million of ROU assets in exchange for $5.3 million of lease liabilities. As of March 31, 2019, we recognized $4.2 million of ROU assets in exchange for $4.2 million of lease liabilities. We elected to (1) not separate “lease components” from “non-lease components” in our measurement of minimum payments for (i) facility leases and (ii) office equipment leases and (2) not recognize a lease asset and liability for a term of 12 months or less. Financial Reporting Captions The below table summarizes these lease asset and liability accounts presented on our accompanying Condensed Consolidated Balance Sheets: Operating Leases* Condensed Consolidated Balance Sheet Caption Balance as of March 31, 2020 Balance as of December 31, 2019 Operating lease right-of-use assets - non-current Facility and equipment under lease $ 3,467 $ 3,806 Operating lease liabilities - current Accounts payable and other accrued liabilities $ 1,725 $ 1,683 Operating lease liabilities - non-current Other long-term liabilities 1,981 2,372 Total operating lease liabilities $ 3,706 $ 4,055 * We had no “finance leases” as of March 31, 2020, as defined in Topic 842 . Components of Lease Expense We recognize lease expense on a straight-line basis over the term of our operating leases, as reported within “selling, general and administrative” expense on the accompanying Condensed Consolidated Statements of Operations. The components of our aggregate lease expense is summarized below: Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 Operating lease cost $ 466 $ 459 Variable lease cost 114 108 Short-term lease cost 15 15 Total lease cost $ 595 $ 583 Weighted Average Remaining Lease Term and Applied Discount Rate Weighted Average Remaining Lease Term Weighted Average Discount Rate Operating leases as of March 31, 2020 2.2 years 7.8% Operating leases as of December 31, 2019 2.5 years 7.8% Future Contractual Lease Payments as of March 31, 2020 The below table summarizes our (i) minimum lease payments over the next five years, (ii) lease arrangement implied interest, and (iii) present value of future lease payments: Operating Leases - future payments March 31, 2020 2020 (remaining) $ 1,458 2021 1,671 2022 828 2023 87 2024 — Total future lease payments, undiscounted $ 4,044 (Less): Implied interest (338) Present value of operating lease payments $ 3,706 (b) In/Out Licensing Agreements and Co-Development Arrangements Overview The in-license agreements for our development-stage drug products provide us with territory-specific rights to their manufacture and distribution (including further sub-licensing/out-licensing rights). We are generally responsible for all related clinical development costs, patent filings and maintenance costs, marketing costs, and liability insurance costs. We are also obligated to make specified milestone payments to our licensors upon the achievement of certain regulatory and sales milestones, and to pay royalties based on our net sales of all in-licensed products. We also may enter into out-license agreements for territory-specific rights to these drug products which include one or more of: upfront license fees, royalties from our licensees’ sales, and/or milestone payments from our licensees’ sales or regulatory achievements. For certain drug products, we may enter into cost-sharing arrangements with licensees and licensors. Impact of Commercial Product Portfolio Transaction on Rights and Obligations Associated with the Product Portfolio In March 2019, we completed the Commercial Product Portfolio Transaction and substantially all of the contractual rights and obligations associated with the Commercial Product Portfolio were transferred to Acrotech at the closing of the Commercial Product Portfolio Transaction. However, under the terms of this transaction we retained our trade “accounts receivable” and GTN liabilities included within “accounts payable and other accrued liabilities” (see Note 3(g) ) associated with our product sales made on and prior to February 28, 2019. Accordingly, these Condensed Consolidated Financial Statements reflect the corresponding revenue-deriving activities and allocable expenses of this commercial business within “discontinued operations” - see Notes 1 and 10 . The most significant remaining agreements associated with our continuing operations are listed below, along with the key financial terms and our corresponding accounting and reporting conventions for each: (i) ROLONTIS: Co-Development and Commercialization Agreement with Hanmi Pharmaceutical Co. Ltd In October 2014, we exercised our option under a License Option and Research Collaboration Agreement dated January 2012 (as amended) with Hanmi Pharmaceutical Co. Ltd., or Hanmi, for ROLONTIS, a drug based on Hanmi’s proprietary LAPSCOVERY™ technology for the treatment of chemotherapy induced neutropenia. Under the terms of this agreement, as amended, we have primary financial responsibility for the ROLONTIS development plan and hold its worldwide rights (except for Korea, China, and Japan). We are contractually obligated to pay Hanmi tiered royalties that range from the low double-digits to mid-teen on our net sales of ROLONTIS. In January 2016, the first patient was dosed with ROLONTIS in a clinical trial. This triggered our contractual milestone payment to Hanmi, and in April 2016, we issued 318,750 shares of our common stock to Hanmi. We are responsible for further contractual payments upon the achievement of a regulatory milestone (triggering $10 million to Hanmi), and sales milestone payments of up to $120 million per calendar year based on our net sales of ROLONTIS. Depending on the milestone achievement type we will either (a) capitalize the value to “intangible assets” in the Consolidated Balance Sheets or (b) recognize the payment value within “research and development” or “cost of sales” on the Consolidated Statements of Operations. The corresponding liability for the payment due to the licensor will be recognized in the Consolidated Balance Sheets within “accounts payable and other accrued liabilities” in the earliest period that we determine the respective milestone achievement is probable or occurs. (ii) Poziotinib: In-License Agreement with Hanmi and Exclusive Patent and Technology License Agreement with MD Anderson In February 2015, we executed an in-license agreement with Hanmi for poziotinib, a pan-HER inhibitor in Phase 2 clinical trials, (which has also shown single agent activity in the treatment of various cancer types during Phase 1 studies, including breast, gastric, colorectal, and lung cancers) and made an upfront payment to Hanmi for these distribution rights. Under the terms of this agreement, we received the exclusive global rights to commercialize poziotinib, except for Korea and China. Hanmi and its development partners are fully responsible for the completion of on-going Phase 2 trials in Korea. We are financially responsible for all other clinical studies. We are obligated to make contractual payments to Hanmi upon our achievement of various regulatory milestones that aggregate $33 million. We are also obligated to pay Hanmi net sales milestones of up to $325 million annually and pay royalties in the low to mid-teen digits on our net sales of poziotinib, potentially reduced by royalties due to other third parties. In April 2018, we executed an exclusive patent and technology agreement for the use of poziotinib in treating patients with EGFR and HER2 exon 20 mutations in cancer and HER2 exon 19 mutations in cancer with The University of Texas M.D. Anderson Cancer Center (“MD Anderson”). MD Anderson discovered poziotinib’s use in treating these patient-types (“Exon 19/20 Patients”). We made an upfront payment to MD Anderson of $0.5 million upon the execution of this agreement that we recognized within “research and development” expense in the Consolidated Statements of Operations for the year ended December 31, 2018. We are contractually obligated to pay nominal fixed annual license maintenance fees to MD Anderson and pay additional fees upon our achievement of various regulatory and sales milestones. These regulatory milestones aggregate $6 million and the sales milestones aggregate $24 million. We are also contractually obligated to pay MD Anderson royalties in the low single-digits on our net sales of poziotinib. Depending on the milestone achievement type we will either (a) capitalize the payment value to “intangible assets” in the Consolidated Balance Sheets or (b) recognize the payment value within “research and development” or “cost of sales” on the Consolidated Statements of Operations. The corresponding liability for the payment due to this licensor will be recognized in the Consolidated Balance Sheets within “accounts payable and other accrued liabilities” in the earliest period that we determine the respective milestone achievement is probable or occurs. (iii) In-License Agreement with ImmunGene for FIT Drug Delivery Platform In April 2019, we executed an asset transfer, license, and sublicense agreement with ImmunGene, Inc. (“ImmunGene”) for an exclusive license for the intellectual property related to (i) Anti-CD20-IFNα, an antibody-interferon fusion molecule directed against CD20 that is in Phase 1 development for treating relapsed or refractory non-Hodgkin’s lymphoma, including diffuse large B-cell lymphoma patients, representing a considerable unmet medical need and (ii) an antibody-interferon fusion molecule directed against GRP94, a target for which currently there are no existing approved therapies that have the potential for treating both solid and hematologic malignancies. Both molecules are based on the Focused Interferon Therapeutics (“FIT”) drug delivery platform. We made upfront payments aggregating $2.8 million to ImmunGene and to several other third parties, all of which were recorded within “research and development” expense within our Consolidated Statements of Operations for the year ended December 31, 2019. We will make further payments to ImmunGene upon our achievement of various regulatory milestones that aggregate $26.1 million, plus an additional $5 million milestone payment for each new indication (beyond those described above) approved for either drug in the U.S., Europe, or Japan. Our contractual royalties to ImmunGene are in the high-single digits on our net sales of each drug, potentially reduced by our royalties due to other third parties. We are also contractually obligated to pay nominal fixed annual license maintenance fees to two licensors. Depending on the nature of the milestone achievement type we will either (a) capitalize the payment value to “intangible assets” in the Consolidated Balance Sheets or (b) recognize the payment value within “research and development” or “cost of sales” within the Consolidated Statements of Operations. The corresponding liability for the payment due to this licensor will be recognized in the Consolidated Balance Sheets within “accounts payable and other accrued liabilities” in the earliest period that we determine the respective milestone achievement is probable or occurs. (c) Service Agreements for Research and Development Activities We have entered into various contracts with numerous third party service providers for the execution of our research and development initiatives (to which we assign project codes in order to compile and monitor such expenses). These vendors include raw material suppliers, clinical trial sites, clinical research organizations, and data monitoring centers, among others. The financial terms of these agreements are varied and generally obligate us to pay in stages, depending on the achievement of certain events specified in the agreements - such as contract execution, progress of service completion, delivery of drug supply, and the dosing of patients in clinical studies. We recognize these “research and development” expenses and corresponding “accounts payable and other accrued liabilities” in the accompanying financial statements based on estimates of our vendors’ progress of performed services, patient enrollments and dosing, completion of clinical studies, and other events. Should we decide to discontinue and/or slow-down the work on any project, the associated costs for those projects would typically be limited to the extent of the work completed, as we are generally able to terminate these contracts with adequate notice. (d) Supply and Service Agreements Associated with Product Production We have various product supply agreements and/or have issued vendor purchase orders that obligate us to agreed-upon raw material purchases from certain vendors. We also have certain drug production service agreements with select contract manufacturers that obligate us to service fees during the contractual period. These collective commitments do not exceed our planned commercial requirements; the corresponding contracted prices do not exceed their current fair market values. (e) Employment Agreements We entered into revised employment agreements with each of our named executive officers (chief executive officer, chief operating officer, chief financial officer, chief legal officer, and chief medical officer) in April/June 2018 and June 2019, which supersede any prior Change in Control Severance Agreements with such individuals. These agreements provide for the payment of certain benefits to each executive upon his separation of employment under specified circumstances. These arrangements are designed to encourage each to act in the best interests of our stockholders at all times during the course of a change in control event or other significant transaction. (f) Deferred Compensation Plan The Spectrum Pharmaceuticals, Inc. Deferred Compensation Plan (the “DC Plan”) is administered by the Compensation Committee of our Board of Directors and is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended. The DC Plan is maintained to provide special deferred benefits for a select group of our employees (the “DC Participants”). DC Participants make annual elections to defer a portion of their eligible cash compensation which is then placed into their DC Plan accounts. We match a fixed percentage of these deferrals, and may make additional discretionary contributions. At March 31, 2020 and December 31, 2019, the aggregate value of this DC Plan liability was $7.4 million and $8.7 million, respectively, and is included within “accounts payable and other accrued liabilities” and “other long-term liabilities” in the accompanying Condensed Consolidated Balance Sheets. (g) Litigation We are involved from time-to-time with various legal matters arising in the ordinary course of business. These claims and legal proceedings are of a nature we believe are normal and incidental to a pharmaceutical business, and may include product liability, intellectual property, employment matters, and other general claims. We may also be subject to derivative lawsuits from time to time. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are assessed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. Although the ultimate resolution of these various matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material adverse effect on our consolidated results of operations, cash flows, or financial condition. Stockholder Litigation Olutayo Ayeni v. Spectrum Pharmaceuticals, Inc., et al. (Filed September 21, 2016 in the United States District Court, Central District of California; Case No. 2:16-cv-07074) (the “Ayeni Action”) and Glen Hartsock v. Spectrum Pharmaceuticals, Inc., et al. (Filed September 28, 2016 in the United States District Court, District Court of Nevada Case; No. 2:16-cv-02279-RFB-GWF) (the “Hartsock Action”). On November 15, 2016, the Ayeni Action was transferred to the United States District Court for the District of Nevada. The parties have stipulated to a consolidation of the Ayeni Action with the Hartsock Action. These class action lawsuits allege that we and certain of our executive officers made false or misleading statements and failed to disclose material facts about our business and the prospects of approval for our New Drug Application to the FDA for QAPZOLA in violation of Section 10(b) (and Rule 10b-5 promulgated thereunder) and 20(a) of the Securities Exchange Act of 1934, as amended. On July 23, 2019, we entered into a memorandum of understanding with these plaintiffs for a collective settlement that is pending court approval. The value of this proposed settlement is included within “other receivables” (see Note 3(d) ) and “accounts payable and other accrued liabilities” (see Note 3(g) ) on the accompanying Condensed Consolidated Balance Sheet as of March 31, 2020.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES Early Adoption of ASU 2019-12 — Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes As of March 31, 2020, we elected to early adopt ASU 2019-12 , “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. Based upon this early adoption, we are not required to calculate an income tax benefit for the three months ended March 31, 2020. We apply an estimated annual effective tax rate (“ETR”) approach for calculating a tax provision for interim periods, as required under GAAP. We recorded a benefit for income taxes from continuing operations of $8.2 million for the three months ended March 31, 2019, in the Condensed Consolidated Statements of Operations. Our ETR differs from the U.S. federal statutory tax rate of 21% primarily as a result of nondeductible expenses and the impact of the valuation allowance on our deferred tax assets. Prior to the early adoption of ASU 2019-12 , and for the three months ended March 31, 2019, the intraperiod tax allocation guidance required that we allocate income taxes between continuing operations and other categories of earnings. When we have a year-to-date pre-tax loss from continuing operations and year-to-date pre-tax income in discontinued operations, ASC 740-20-45-7 required that we allocate the income tax provision to other categories of earnings (including discontinued operations), and then record a related tax benefit in continuing operations. For the three months ended March 31, 2020 and 2019, we recognized net income from discontinued operations while sustaining losses from continuing operations. Because of the required allocation, we recorded an income tax benefit of $8.2 million for the three months ended March 31, 2019, within “benefit for income taxes from continuing operations” and income tax expense of $6.7 million within “income from discontinued operations, net of income taxes” on the accompanying Condensed Consolidated Statements of Operations. Our net tax benefit for the three months ended March 31, 2019, prior to the application of intraperiod tax allocation guidance was $1.5 million. This tax benefit arose from the reversal of deferred tax liabilities recorded on our Consolidated Balance Sheet as of December 31, 2018 that were associated with indefinite-lived intangible assets that were sold as part of our Commercial Product Portfolio Transaction.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	DISCONTINUED OPERATIONS Overview In March 2019, we completed the Commercial Product Portfolio Transaction -- see Note 1(b) (we first announced the Commercial Product Portfolio Transaction on January 17, 2019 on Form 8-K, upon the signing of the definitive asset purchase agreement). In accordance with applicable GAAP ( ASC 205-20, Presentation of Financial Statements ), the revenue-deriving activities and allocable expenses of our sold commercial operation, connected to the Commercial Product Portfolio, are separately classified as “discontinued” for all periods presented within the accompanying Condensed Consolidated Statements of Operations. See Note 13 for a discussion of certain immaterial corrections affecting the presented amounts below. Condensed Consolidated Statements of Operations The following table presents the various elements of “income from discontinued operations, net of income taxes” as reported in the accompanying Condensed Consolidated Statements of Operations (inclusive of the immaterial corrections as discussed in Note 13 ): Three Months Ended 2020 2019 Revenues: Product sales, net* $ (220) $ 14,079 License fees and service revenue — 290 Total revenues $ (220) $ 14,369 Operating costs and expenses: Cost of sales (excluding amortization of intangible assets) (229) 3,168 Selling, general and administrative (1) 5,951 Research and development (35) 2,536 Amortization of intangible assets — 1,248 Restructuring charges - employee severance ( Note 11 ) — 6,297 Total operating costs and expenses $ (265) $ 19,200 Income (loss) from discontinued operations $ 45 $ (4,831) Other (expense) income: Change in fair value of contingent consideration — (1,478) Gain on sale of Commercial Product Portfolio** — 33,644 Total other (expense) income $ — $ 32,166 Income from discontinued operations before income taxes 45 27,335 Provision for income taxes from discontinued operations*** — (6,748) Income from discontinued operations, net of income taxes $ 45 $ 20,587 * This revenue for the three months ended March 31, 2019 includes: (i) sales from our Commercial Product Portfolio in January and February 2019 (prior to the completion of the Commercial Product Portfolio Transaction) and (ii) EVOMELA sales to a specific licensee (see Note 7 ). This amount was corrected to reflect the immaterial error identified by management as described above (see Note 13 ). ** The pre-tax gain on sale for the three months ended March 31, 2019 represents the $158.8 million gross proceeds from the Commercial Product Portfolio Transaction less our $121.2 book value of transferred net assets (inclusive of assumed liabilities) to Acrotech on the March 1, 2019 closing date less legal and banker fees aggregating $3.9 million. *** Given the immaterial error corrections identified above, there was a corresponding tax impact for the three months ended March 31, 2019. This income tax provision represents an allocation of taxes as required under intraperiod allocation guidance that was in affect at that time (see Note 9 ). This amount was corrected to reflect the immaterial error identified by management as described above (see Note 13 ). Condensed Consolidated Balance Sheets Accounts receivable derived from our product sales on and prior to February 28, 2019 were not transferred to Acrotech as part of Commercial Product Portfolio Transaction, nor were our GTN liabilities and trade accounts payable assumed by Acrotech that were associated with our commercial activities on and prior to February 28, 2019 (see Note 3(g) ). Accordingly, these specific assets and liabilities remain presented within “accounts receivable, net of allowance for credit losses” and “accounts payable and other accrued liabilities” on the accompanying Condensed Consolidated Balance Sheets. Condensed Consolidated Statement of Cash Flows The following table presents significant non-cash items for our discontinued operations that are included as adjustments in the accompanying Condensed Consolidated Statements of Cash Flows: Three Months Ended 2020 2019 Depreciation and amortization $ — $ 1,263 Stock-based compensation $ — $ 3,405 Change in fair value of contingent consideration $ — $ 1,478

Restructuring Costs Related To

Restructuring Costs Related To Sale Of Commercial Product Portfolio	3 Months Ended
	Mar. 31, 2020
Restructuring and Related Activities [Abstract]
Restructuring Costs Related To Sale Of Commercial Product Portfolio	RESTRUCTURING COSTS RELATED TO SALE OF COMMERCIAL PRODUCT PORTFOLIO Employee Severance On March 1, 2019, we completed the Commercial Product Portfolio Transaction (see Note 1(b) ) and 87 of our employees were (1) terminated March 1, 2019 or (2) given notice of May 31, 2019 termination and asked to provide transition services for the benefit of Acrotech through that date (as provided by a transition services agreement with Acrotech entered contemporaneously with our sale). For the three months ended March 31, 2019, we recognized $0.2 million of income for services rendered to Acrotech under this agreement within “other expense, net” on our accompanying Condensed Consolidated Statements of Operations. The employees in (1) above were entitled to cash severance payments and acceleration of their unvested restricted stock awards and stock options. For the three months ended March 31, 2019, we fully recognized the aggregate value of $8.3 million for this severance benefit, of which $6.3 million, $1.5 million, and $0.5 million is included on the accompanying Condensed Consolidated Statements of Operations within “income from discontinued operations, net of income taxes” (see Note 10 ), “selling, general, and administrative” expenses and “research and development” expenses, respectively. The employees in (2) above were also entitled to cash severance payments and acceleration of their unvested restricted stock awards and stock options, though on May 31, 2019. The aggregate value of these one-time cash payments and stock-based award accelerations was $0.5 million. Due to then ongoing service requirements of these employees, we amortized this value through expense on a ratable basis beginning March 1, 2019 through May 31, 2019. For the three months ended March 31, 2019, we recognized $0.2 million for this severance benefit, which is included within “selling, general, and administrative” expenses on the accompanying Condensed Consolidated Statements of Operations, and within “accrued payroll and benefits” and “additional paid-in capital” (for stock-based awards) on the accompanying Condensed Consolidated Balance Sheets as of March 31, 2019. Unpaid cash severance for our former employees was $0.2 million and $1.1 million at March 31, 2020 and March 31, 2019, respectively, and is recorded within “accrued payroll and benefits” on the accompanying Condensed Consolidated Balance Sheets.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Equity	STOCKHOLDERS’ EQUITY Sale of Common Stock Under ATM Agreement On April 5, 2019, we entered into a new collective at-market-issuance (ATM) sales agreement with Cantor Fitzgerald & Co., H.C. Wainwright & Co., LLC and B. Riley FBR, Inc. (the “April 2019 ATM Agreement”). The sales agreement prospectus filed with our shelf registration statement on Form S-3, filed with the SEC on March 20, 2020, registers an aggregate offering price of $75 million under the April 2019 ATM Agreement. Through March 31, 2020, we raised aggregate net proceeds of $1.8 million under the April 2019 ATM Agreement, pursuant to an automatic shelf registration statement on Form S-3, filed with the SEC on April 5, 2019. These proceeds and any future proceeds raised will support the advancement of our in-development drug candidates, activities in connection with the launch of these drugs (including the hiring of personnel, building inventory supply and equipment purchases), completing acquisitions of assets, businesses, or securities, and for all other working capital purposes. Description of Financing Transaction No. of Common Shares Issued Proceeds Received Common shares issued pursuant to the April 2019 ATM Agreement during the year ended December 31, 2019 221,529 $ 1,814

Immaterial Restatement of Prior

Immaterial Restatement of Prior Period Financial Statements	3 Months Ended
	Mar. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Immaterial Restatement of Prior Period Financial Statements	IMMATERIAL RESTATEMENT OF PRIOR PERIOD FINANCIAL STATEMENTS Subsequent to the issuance of our unaudited interim financial statements for the quarter ended March 31, 2019, and prior to the issuance of our Form 10-K for the year ended December 31, 2019, management identified certain immaterial errors aggregating $12.0 million that substantially relates to our ZEVALIN pricing to qualifying Public Health Service hospitals from 2009 through March 31, 2019. This accumulated value resulted from a mistaken one-time “market date” load into the Centers for Medicare and Medicaid Services system for this drug. We erroneously used the year we in-licensed this product of 2009, rather than its original sale year of 2002. We previously restated our Consolidated Financial Statements for the years ended December 2018 and 2017, respectively, to correct the error. The impact of this correction to the three months ended March 31, 2019 is presented below. We have restated our accompanying Condensed Consolidated Financial Statements to correct for these immaterial errors for the prior-year interim period presented on each face financial statement (as summarized below), as well as the correction of "product sales, net" - presented within Note 10 for our discontinued operations. Condensed Consolidated Statement of Operations for the three months ended March 31, 2019: As Previously Reported Adjustments for Error Corrections As Restated Benefit for income taxes from continuing operations $ 8,242 $ (26) $ 8,216 Loss from continuing operations (39,820) (26) (39,846) Income from discontinued operations, net of income taxes ( Note 10 ) 20,665 (78) 20,587 Net loss (19,155) (104) (19,259) Condensed Consolidated Statement of Comprehensive Loss for the three months ended March 31, 2019: As Previously Reported Adjustments for Error Corrections As Restated Net loss $ (19,155) $ (104) $ (19,259) Total comprehensive loss (19,545) (104) (19,649) Condensed Consolidated Statement of Stockholders’ Equity and Cash Flow: The Condensed Consolidated Statement of Stockholders’ Equity for the three months ended March 31, 2019, has also been restated to include the changes to “net loss” summarized above and to reflect the correction of accumulated deficit as of December 31, 2018 from $599,886 to $611,738. These errors had no impact on our Condensed Consolidated Statement of Cash Flow, except for the offsetting corrections between "net loss" and changes in "accounts payable and other accrued liabilities" presented within "net cash used in operating activities."

Description of Business, Basi_2

Description of Business, Basis of Presentation, and Operating Segment (Policies)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Spectrum Pharmaceuticals, Inc. (“Spectrum”, the “Company”, “we”, “our”, or “us”) is a biopharma company, with a primary strategy comprised of acquiring, developing, and commercializing novel and targeted oncology therapies. Our in-house development organization includes clinical development, regulatory, quality and data management. We plan to build out our commercial and marketing capabilities in the second half of 2020 to prepare for the launch of ROLONTIS. We have three drugs in development: • ROLONTIS, a novel long-acting granulocyte colony-stimulating (“G-CSF”) for chemotherapy-induced neutropenia which has been filed with the FDA and has a Prescription Drug User Fee Act (“PDUFA”) date of October 24, 2020; • Poziotinib, a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer (“NSCLC”) tumors with various mutations; and • Anti-CD20-IFNα, an interferon fusion molecule directed against CD20 that is in Phase 1 development for treating relapsed or refractory non-Hodgkin’s lymphoma (“NHL”) patients (including diffuse large B-cell lymphoma).
Basis of Presentation	Basis of Presentation Interim Financial Statements The interim financial data for the three months ended March 31, 2020 and 2019 is unaudited and is not necessarily indicative of our operating results for a full year. In the opinion of our management, the interim data includes normal and recurring adjustments necessary for a fair presentation of our financial results for the three months ended March 31, 2020 and 2019. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to the Securities and Exchange Commission (“SEC”) rules and regulations relating to interim financial statements. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and Notes thereto included within our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (filed with the SEC on March 2, 2020). Discontinued Operations - Sale of our Commercial Product Portfolio On March 1, 2019, we completed the sale of our seven then-commercialized drugs, including FUSILEV, KHAPZORY, FOLOTYN, ZEVALIN , MARQIBO, BELEODAQ, and EVOMELA (the “Commercial Product Portfolio”) to Acrotech Biopharma LLC (“Acrotech”) (the “Commercial Product Portfolio Transaction”). Upon closing we received $158.8 million in an upfront cash payment (of which $4 million was held in escrow until November 2019). We are also entitled to receive up to an aggregate of $140 million upon Acrotech's future achievement of certain regulatory milestones (totaling $40 million) and sales-based milestones (totaling $100 million) relating to the Commercial Product Portfolio. These Condensed Consolidated Financial Statements reflect the corresponding revenue-deriving activities and allocable expenses of this commercial business within “discontinued operations” - see Note 10 . We have presented our face financial statements in general conformity with our historical format, even where presented values are $-0- within continuing operations due to required discontinued operations classification for all periods presented. We believe this format provides increased clarity and comparability with our previously filed financial statements, as well as our expectation that these financial statement captions and associated footnote disclosures will remain relevant to our future business activities. Principles of Consolidation
Operating Segment	Operating Segment We operate one reportable operating segment that is focused exclusively on developing (and eventually marketing) oncology and hematology drug products. For the three months ended March 31, 2020 and 2019, all of our revenue and operating costs and expenses were solely attributable to these activities (and as applicable, classified as “discontinued” within the accompanying Condensed Consolidated Statements of Operations - see Note 10 ). All of our assets are held in the U.S, except for cash held in certain foreign bank accounts.
Revenue Recognition	Revenue Recognition On March 1, 2019, we completed the Commercial Product Portfolio Transaction -- see Note 1(b) . In accordance with applicable GAAP ( ASC 205-20, Presentation of Financial Statements ), the revenue-deriving activities of our sold commercial operation are separately classified as “discontinued” for all periods presented within the accompanying Condensed Consolidated Statements of Operations -- see Note 10 . Required Elements of Our Revenue Recognition : Revenue from our (a) product sales, (b) out-license arrangements, and (c) service arrangements is recognized under Accounting Standards Update (“ ASU ”) No. 2014-09 , Revenue from Contracts with Customers ( “Topic 606” ) in a manner that reasonably reflects the delivery of our goods and/or services to customers in return for expected consideration and includes the following elements: (1) we ensure that we have an executed contract(s) with our customer that we believe is legally enforceable; (2) we identify the “performance obligations” in the respective contract; (3) we determine the “transaction price” for each performance obligation in the respective contract; (4) we allocate the transaction price to each performance obligation; and (5) we recognize revenue only when we satisfy each performance obligation. These five elements, as applied to each of our revenue categories, are summarized below: (a) Product Sales : We sell our products to pharmaceutical wholesalers/distributors or to our product licensees (i.e., our customers). Our wholesalers/distributors in turn sell our products directly to clinics, hospitals, and private oncology-based practices. Revenue from our product sales is recognized as physical delivery of product occurs (when our customer obtains control of the product), in return for agreed-upon consideration. Our gross product sales (i.e., delivered units multiplied by the contractual price per unit) are reduced by our corresponding gross-to-net (“GTN”) estimates using the “expected value” method, resulting in reported “product sales, net” that reflects the amount we ultimately expect to realize in net cash proceeds, taking into account our current period gross sales and related cash receipts, and the subsequent cash disbursements on these sales that we estimate for the various GTN categories discussed below. These estimates are based upon information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and sales to end-users during the period), in combination with management’s informed judgments. Due to the inherent uncertainty of these estimates, the actual amount incurred (of some, or all) of product returns, government chargebacks, prompt pay discounts, commercial rebates, Medicaid rebates, and distribution, data, and GPO administrative fees may be materially above or below the amount estimated, then requiring prospective adjustments to our reported net product sales. These GTN estimate categories (that comprise our GTN liabilities within Note 3(g) ) are each discussed below: Product Returns Allowances : Our customers are contractually permitted to return certain purchased products within the contractual allowable time before/after its applicable expiration date. Returns outside of this aforementioned criteria are not customarily allowed. We estimate expected product returns using our historical return rates. Returned product is typically destroyed since substantially all are due to its imminent expiry and cannot be resold. Government Chargebacks : Our products are subject to pricing limits under certain federal government programs (e.g., Medicare and 340B Drug Pricing Program). Qualifying entities (i.e., end-users) purchase products from our customers at their qualifying discounted price. The chargeback amount we incur represents the difference between our contractual sales price to our customer, and the end-user’s applicable discounted purchase price under the government program. There may be significant lag time between our reported net product sales and our receipt of the corresponding government chargeback claims from our customers. Prompt Pay Discounts : Discounts for prompt payment are estimated at the time of sale, based on our eligible customers’ prompt payment history and the contractual discount percentage. Commercial Rebates : Commercial rebates are based on (i) our estimates of end-user purchases through a group purchasing organization (“GPO”), (ii) the corresponding contractual rebate percentage tier we expect each GPO to achieve, and (iii) our estimates of the impact of any prospective rebate program changes made by us. Medicaid Rebates : Our products are subject to state government-managed Medicaid programs, whereby rebates are issued to participating state governments. These rebates arise when a patient treated with our product is covered under Medicaid, resulting in a discounted price for our product under the applicable Medicaid program. Our Medicaid rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time lag in our receiving rebate notices from each state (generally several months or longer after our sale is recognized). Our estimates are based on our historical claim levels by state, as supplemented by management’s judgment. Distribution, Data, and GPO Administrative Fees : Distribution, data, and GPO administrative fees are paid to authorized wholesalers/distributors of our products for various commercial services including: contract administration, inventory management, delivery of end-user sales data, and product returns processing. These fees are based on a contractually-determined percentage of our applicable sales. (b) License Fees : Our out-license arrangements allow licensees to market our product(s) in certain territories for a specific term (representing the out-license of “functional intellectual property”). These arrangements may include one or more of the following forms of consideration: (i) upfront license fees, (ii) sales royalties, (iii) sales milestone-achievement fees, and (iv) regulatory milestone-achievement fees. We recognize revenue for each based on the contractual terms that establish our right to collect payment once the performance obligation is achieved, as follows: (1) Upfront License Fees: We determine whether upfront license fees are earned at the time of contract execution (i.e., when rights transfer to the customer) or over the actual (or implied) contractual period of the out-license. As part of this determination, we evaluate whether we have any other requirements to provide substantive services that are inseparable from the performance obligation of the license transfer. Our customers’ “distinct” rights to licensed “functional intellectual property” at the time of contract execution results in concurrent revenue recognition of all upfront license fees (assuming that there are no other performance obligations at contract execution that are inseparable from this license transfer). (2) Royalties : Under the “sales-or-usage-based royalty exception” we recognize revenue in the same period that our licensees complete product sales in their territory for which we are contractually entitled to a percentage-based royalty receipt. (3) Sales Milestones : Under the “sales-or-usage-based royalty exception” we recognize revenue in full within the period that our licensees achieve annual or aggregate product sales levels in their territories for which we are contractually entitled to a specified lump-sum receipt. (4) Regulatory Milestones : Under the terms of the respective out-license, regulatory achievements may either be our responsibility, or that of our licensee. • When our licensee is responsible for the achievement of the regulatory milestone, we recognize revenue in full (for the contractual amount due from our licensee) in the period that the approval occurs (i.e., when the “performance obligation” is satisfied by our customer) under the “most likely amount” method. This revenue recognition remains “constrained” (i.e., not recognized) until regulatory approval occurs, given its inherent uncertainty and the requirement of a significant revenue reversal not being probable if achievement does not occur. At each reporting period, we re-evaluate the probability of milestone achievement and the associated revenue constraint; any resulting adjustments would be recorded on a cumulative catch-up basis, thus reflected in our financial statements in the period of adjustment. • When we are responsible for the achievement of a regulatory milestone, the “relative selling price method” is applied for purposes of allocating the transaction price to our performance obligations. In such case, we consider (i) the extent of our effort to achieve the milestone and/or the enhancement of the value of the delivered item(s) as a result of milestone achievement and (ii) if the milestone payment is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement. We have historically assessed the contractual value of these milestones upon their achievement to be identical to the allocation of value of our performance obligations and thus representing the “transaction price” for each milestone at contract inception. We recognize this revenue in the period that the regulatory approval occurs (i.e., when we complete the “performance obligation”) under the “most likely amount” method, and revenue recognition is otherwise “constrained” until regulatory approval occurs, given its inherent uncertainty and the requirement of a significant revenue reversal not being probable if achievement does not occur. At each reporting period, we re-evaluate the probability of milestone achievement and the associated revenue constraint; any resulting adjustments would be recorded on a cumulative catch-up basis, thus reflected in our financial statements in the period of adjustment. (c) Service Revenue : We receive fees under certain arrangements for (i) sales and marketing services, (ii) supply chain services, (iii) research and development services, and (iv) clinical trial management services. Our rights to receive payment for these services may be established by (1) a fixed-fee schedule that covers the term of the arrangement, so long as we meet ongoing performance obligations, (2) our completion of product delivery in our capacity as a procurement agent, (3) the successful completion of a phase of drug development, (4) favorable results from a clinical trial, and/or (5) regulatory approval events.
Cash and Cash Equivalents	Cash and Cash EquivalentsCash and cash equivalents consist of bank deposits and highly liquid investments with maturities of three months or less from the purchase date.
Marketable Securities	Marketable SecuritiesMarketable securities consist of our holdings in equity securities, mutual funds, bank certificates of deposit (“Bank CDs”), government-related debt securities, and corporate debt securities. Since we classify these investments as “available-for-sale” any (1) realized gains (losses) or (2) unrealized gains (losses) on these securities are respectively recognized in (1) “other expense, net” on the accompanying Condensed Consolidated Statements of Operations, or (2) depending on the nature of the marketable securities recognized in “accumulated other comprehensive loss” as a separate component of stockholder’s equity on the accompanying Condensed Consolidated Statements of Stockholders’ Equity, or in “other expense, net” on the accompanying Condensed Consolidated Statements of Operations.
Accounts Receivable	Accounts Receivable Our accounts receivable, net of allowance for credit losses are derived from our product sales and license fees, and do not bear interest. The allowance for credit losses is management’s best estimate of the amount of expected credit losses in our existing accounts receivable and any anticipated discounts. The allowance for credit losses is adjusted each period through earnings to reflect expected credit losses over the remaining life of the asset. Account balances are written off against the allowance after appropriate collection efforts are exhausted. In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13 ("ASU 2016-13") "Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" , which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This new ASU replaces the existing incurred loss impairment model with a current expected credit loss model (“CECL”), which requires the use of forward-looking information to calculate credit loss estimates. The new CECL model requires recognition of credit losses for loans and other receivables at the time the financial asset is originated or acquired, in which the expected credit losses are adjusted each period for changes in expected lifetime credit losses. The new standard also applies to receivables arising from revenue transactions such as contract assets and accounts receivables and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. We adopted ASU 2016-13 as of January 1, 2020, which had no material effect on our accompanying Condensed Consolidated Financial Statements.
Property and Equipment	Property and EquipmentOur property and equipment is stated at historical cost, and is depreciated on a straight-line basis over an estimated useful life that corresponds with its designated asset category. We evaluate the recoverability of “long-lived assets” (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset’s carrying amount may not be recoverable through our on-going operations.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense for equity awards granted to our employees and members of our Board of Directors is recognized on a straight-line basis over each award’s vesting period. Recognized compensation expense is net of an estimated forfeiture rate, representing the percentage of awards that are expected to be forfeited prior to vesting, though is ultimately adjusted for actual forfeitures. We use the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) that have service conditions for vesting. We use the Monte Carlo valuation model to value equity awards (as of the date of grant) that have combined market conditions and service conditions for vesting. The recognition of stock-based compensation expense and the initial calculation of stock option fair value requires uncertain assumptions, including (a) the pre-vesting forfeiture rate of the award, (b) the expected term that the stock option will remain outstanding, (c) our stock price volatility over the expected term (and that of our designated peer group with respect to certain market-based awards), and (d) the prevailing risk-free interest rate for the period matching the expected term.
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per ShareWe calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period.
Income Taxes	Income Taxes Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We have recorded a valuation allowance to reduce our deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when we were to determine that our deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase our net income in the period that such determination was made. In the event that we are assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included in “benefit for income taxes from continuing operations” within the accompanying Condensed Consolidated Statements of Operations for the period in which we received the notice.
Research and Development Costs	Research and Development Costs Our research and development costs are expensed as incurred (see Note 8(c) ) or as certain milestone payments become contractually due to our licensors, as triggered by the achievement of clinical or regulatory events.
Fair Value Measurements	Fair Value Measurements We determine measurement-date fair value based on the proceeds that would be received through the sale of the asset, or that we would pay to settle or transfer the liability, in an orderly transaction between market participants. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date. Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public.

Balance Sheet Account Detail (T

Balance Sheet Account Detail (Tables)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash, Cash Equivalents and Investments	The following is a summary of our presented composition of “cash and cash equivalents” and “marketable securities”: Historical or Amortized Cost Foreign Currency Translation Unrealized Cash and Cash Marketable Securities March 31, 2020 Equity securities (see Note 7 ) $ 6,310 $ (2,789) $ 16,976 $ — $ 20,497 $ — $ 20,497 Money market funds 54,282 — — — 54,282 54,282 — Government-related debt securities* 50,113 — 324 — 50,437 10,000 40,437 Corporate debt securities* 33,888 — 15 (159) 33,744 — 33,744 Bank deposits 6,070 — — — $ 6,070 6,070 — Mutual funds 4,941 — — (298) 4,643 — 4,643 Bank CDs 8,088 — 32 — 8,120 — 8,120 Total cash and cash equivalents and marketable securities $ 163,692 $ (2,789) $ 17,347 $ (457) $ 177,793 $ 70,352 $ 107,441 December 31, 2019 Equity securities (see Note 7 ) $ 6,310 $ (2,477) $ 27,214 $ — $ 31,047 $ — $ 31,047 Money market funds 54,199 — — — 54,199 54,199 — Government-related debt securities* 62,617 — 19 (10) 62,626 — 62,626 Corporate debt securities* 58,235 — 38 (25) 58,248 5,000 53,248 Bank deposits 5,219 — — — 5,219 5,219 — Mutual funds 4,375 — 783 — 5,158 — 5,158 Bank CDs 7,354 — 22 — 7,376 — 7,376 Total cash and cash equivalents and marketable securities $ 198,309 $ (2,477) $ 28,076 $ (35) $ 223,873 $ 64,418 $ 159,455 * Beginning in the second quarter of 2019, we purchased certain government-related and corporate debt securities. We have classified these as “available-for-sale” since we may redeem or sell these investments before their stated maturity to fund our operations. Under the requirements of ASC 320, Investments - Debt and Equity Securities: (i) we recorded these securities at initial “book value” and then amortize, through maturity, the determined “discount” or “premium” within “interest income” on the accompanying Condensed Consolidated Statements of Operations, and (ii) we recognize the “unrealized gains (loss)” of these securities (i.e., fair value versus
Schedule of Property and Equipment Net of Accumulated Depreciation	“Property and equipment, net of accumulated depreciation” consists of the following: March 31, 2020 December 31, 2019 Manufacturing equipment* $ 10,815 $ 10,355 Computer hardware and software 3,734 3,606 Laboratory equipment 36 36 Leasehold improvements 3,374 3,374 Office furniture 248 248 Property and equipment, at cost 18,207 17,619 (Less): Accumulated depreciation (6,149) (6,012) Property and equipment, net of accumulated depreciation $ 12,058 $ 11,607 * This account is comprised of our owned ROLONTIS production equipment on location at our contract manufacturer. This equipment has alternative future use for the general production of various biologic agents. Accordingly, we have capitalized these purchases, rather than
Prepaid Expenses and Other Assets	“Prepaid expenses and other assets” consists of the following: March 31, 2020 December 31, 2019 Vendor deposits $ 9,285 $ 8,740 Prepaid insurance 978 1,408 Prepaid expenses and other assets $ 10,263 $ 10,148
Schedule of Other Receivables	“Other receivables” consists of the following: March 31, 2020 December 31, 2019 Insurance receivable* $ 3,337 $ 4,015 CASI other receivables 2,135 2,393 Other miscellaneous receivables 1,385 1,490 Income tax receivable - current portion 1,306 973 Interest receivable from marketable securities (see Note 3(a) ) 497 561 Reimbursements due from development partners for incurred research and development expenses 129 126 Other receivables $ 8,789 $ 9,558 * This insurance receivable balance represents our incurred legal fees and pending and completed settlements that are expected to be reimbursed by our insurance carriers.
Summary of Other Assets	“Other assets” consists of the following: March 31, 2020 December 31, 2019 Key employee life insurance – cash surrender value (associated with deferred compensation plan - see Note 6 ) $ 3,073 $ 3,547 Income tax receivable - non-current portion* — 334 Research & development supplies and other 114 119 Other assets $ 3,187 $ 4,000 * This value was moved to “other receivables” within “total current assets” as the “Coronavirus Aid, Relief and Economic Security (CARES) Act” now allows the immediate refund of alternative minimum tax payments. Previously this amount was expected to be collected over several years (see Note 9 ).
Facility and Equipment Under Lease	“Facility and equipment under lease” consists of the following: March 31, 2020 December 31, 2019 Office and research facilities $ 3,077 $ 3,391 Office equipment 390 415 Facility and equipment under lease $ 3,467 $ 3,806 The below table summarizes these lease asset and liability accounts presented on our accompanying Condensed Consolidated Balance Sheets: Operating Leases* Condensed Consolidated Balance Sheet Caption Balance as of March 31, 2020 Balance as of December 31, 2019 Operating lease right-of-use assets - non-current Facility and equipment under lease $ 3,467 $ 3,806 Operating lease liabilities - current Accounts payable and other accrued liabilities $ 1,725 $ 1,683 Operating lease liabilities - non-current Other long-term liabilities 1,981 2,372 Total operating lease liabilities $ 3,706 $ 4,055 * We had no “finance leases” as of March 31, 2020, as defined in Topic 842 .
Schedule of Accounts Payable and Other Accrued Liabilities	“Accounts payable and other accrued liabilities” consists of the following : March 31, 2020 December 31, 2019 Trade accounts payable and other $ 26,937 $ 32,012 Lease liability - current portion 1,725 1,683 Accrued commercial/Medicaid rebates 2,870 2,925 Accrued product royalty due to licensors — 66 Allowance for product returns 4,714 4,714 Accrued data and distribution fees 768 768 Accrued GPO administrative fees 6 6 Accrued inventory management fees 364 364 Allowance for government chargebacks 11,746 11,746 Accounts payable and other accrued liabilities $ 49,130 $ 54,284
Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities	Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for our categories of GTN estimates (see Note 2(i) ) were as follows: Commercial/Medicaid Rebates and Government Chargebacks* Distribution, Data, Inventory and Product Return Allowances Balance as of December 31, 2018 $ 22,952 $ 3,932 $ 5,171 Add: GTN accruals recorded for product sales 7,702 1,209 167 (Less): Payments made and credits against GTN accruals (15,983) (4,003) (624) Balance as of December 31, 2019 $ 14,671 $ 1,138 $ 4,714 Add: GTN accruals recorded for product sales — — — (Less): Payments made and credits against GTN accruals (55) — — Balance as of March 31, 2020 $ 14,616 $ 1,138 $ 4,714
Summary of Other Long-Term Liabilities	“Other long-term liabilities” consists of the following: March 31, 2020 December 31, 2019 Deferred compensation liability ( Note 8(f) ) $ 6,444 $ 8,597 Lease liability - non-current portion ( Note 8(a) ) 1,981 2,372 Other tax liabilities 101 101 Other long-term liabilities $ 8,526 $ 11,070

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Summary of Stock-Based Compensation Expense	Stock-based compensation expense, included within “total operating costs and expenses” for the three months ended March 31, 2020 and 2019, was as follows: Three Months Ended 2020 2019 Selling, general and administrative $ 3,877 $ 3,626 Research and development 1,398 969 Total stock-based compensation* $ 5,275 $ 4,595 * Beginning in March 2020, we granted 1,650,000 stock-appreciation rights (“SARs”) to our Named Executive Officers. The fair value of these SARs was estimated on the date of grant using the Black-Scholes option-pricing model. These SARs had 25% immediate vesting on the date of grant resulting in recognized stock-based compensation expense of $0.7 million and $0, respectively, within our Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Computation of Net Loss Per Share	Net loss per share was computed by dividing net loss by the weighted average number of common shares outstanding for the three months ended March 31, 2020 and 2019: Three Months Ended 2020 2019 Weighted average shares outstanding - basic and diluted 111,780,571 109,552,602 Net loss $ (40,572) $ (19,259) Net loss per share – basic and diluted $ (0.36) $ (0.18)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Summary of Asset and Liability Fair Values	The table below summarizes certain asset and liability fair values that are included within our accompanying Condensed Consolidated Balance Sheets, and their designations among the three fair value measurement categories (see Note 2(x)) : March 31, 2020 Level 1 Level 2 Level 3 Total Assets: Government-related debt securities $ 35,411 $ 15,026 $ — $ 50,437 Corporate debt securities — 33,744 — 33,744 Money market funds 54,282 — — 54,282 Equity securities ( Note 7 ) 20,497 — — 20,497 Bank CDs — 8,120 — 8,120 Mutual funds 4,643 9 — 4,652 Key employee life insurance, cash surrender value - Note 3(e) ) — 3,073 — 3,073 * $ 114,833 $ 59,972 $ — $ 174,805 Liabilities: Deferred executive compensation liability ( Note 8(f) ) $ — $ 7,447 $ — $ 7,447 * $ — $ 7,447 $ — $ 7,447 December 31, 2019 Level 1 Level 2 Level 3 Total Assets: Government-related debt securities $ 47,636 $ 14,990 $ — $ 62,626 Corporate debt securities — 58,248 — 58,248 Money market funds 54,199 — — 54,199 Equity securities ( Note 7 ) 31,047 — — 31,047 Bank CDs — 7,376 — 7,376 Mutual funds 5,158 11 — 5,169 Key employee life insurance, cash surrender value - Note 3(e) ) — 3,547 — 3,547 * $ 138,040 $ 84,172 $ — $ 222,212 Liabilities: Deferred executive compensation liability ( Note 8(f) ) $ — $ 8,746 $ — $ 8,746 * $ — $ 8,746 $ — $ 8,746 * The reported amount of “key employee life insurance, cash surrender value” is based on the stated cash surrender value of life insurance policies of named current and former employees at each period-end. The reported amount of “deferred executive compensation liability” is based on the period-end market value of mutual fund investments selected by employee participants of the deferred compensation plan.

Financial Commitments & Conti_2

Financial Commitments & Contingencies and Key License Agreements (Tables)	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Summary of Lease assets and Liabilities	“Facility and equipment under lease” consists of the following: March 31, 2020 December 31, 2019 Office and research facilities $ 3,077 $ 3,391 Office equipment 390 415 Facility and equipment under lease $ 3,467 $ 3,806 The below table summarizes these lease asset and liability accounts presented on our accompanying Condensed Consolidated Balance Sheets: Operating Leases* Condensed Consolidated Balance Sheet Caption Balance as of March 31, 2020 Balance as of December 31, 2019 Operating lease right-of-use assets - non-current Facility and equipment under lease $ 3,467 $ 3,806 Operating lease liabilities - current Accounts payable and other accrued liabilities $ 1,725 $ 1,683 Operating lease liabilities - non-current Other long-term liabilities 1,981 2,372 Total operating lease liabilities $ 3,706 $ 4,055 * We had no “finance leases” as of March 31, 2020, as defined in Topic 842 .
Components of Aggregate Lease Expense	The components of our aggregate lease expense is summarized below: Three Months Ended March 31, 2020 Three Months Ended March 31, 2019 Operating lease cost $ 466 $ 459 Variable lease cost 114 108 Short-term lease cost 15 15 Total lease cost $ 595 $ 583 Weighted Average Remaining Lease Term and Applied Discount Rate Weighted Average Remaining Lease Term Weighted Average Discount Rate Operating leases as of March 31, 2020 2.2 years 7.8% Operating leases as of December 31, 2019 2.5 years 7.8%
Future Contractual Lease Payments	The below table summarizes our (i) minimum lease payments over the next five years, (ii) lease arrangement implied interest, and (iii) present value of future lease payments: Operating Leases - future payments March 31, 2020 2020 (remaining) $ 1,458 2021 1,671 2022 828 2023 87 2024 — Total future lease payments, undiscounted $ 4,044 (Less): Implied interest (338) Present value of operating lease payments $ 3,706
Schedule of Contractual Lease Payments

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Condensed Consolidated Statements of Operations and Cash Flows	Three Months Ended 2020 2019 Revenues: Product sales, net* $ (220) $ 14,079 License fees and service revenue — 290 Total revenues $ (220) $ 14,369 Operating costs and expenses: Cost of sales (excluding amortization of intangible assets) (229) 3,168 Selling, general and administrative (1) 5,951 Research and development (35) 2,536 Amortization of intangible assets — 1,248 Restructuring charges - employee severance ( Note 11 ) — 6,297 Total operating costs and expenses $ (265) $ 19,200 Income (loss) from discontinued operations $ 45 $ (4,831) Other (expense) income: Change in fair value of contingent consideration — (1,478) Gain on sale of Commercial Product Portfolio** — 33,644 Total other (expense) income $ — $ 32,166 Income from discontinued operations before income taxes 45 27,335 Provision for income taxes from discontinued operations*** — (6,748) Income from discontinued operations, net of income taxes $ 45 $ 20,587 * This revenue for the three months ended March 31, 2019 includes: (i) sales from our Commercial Product Portfolio in January and February 2019 (prior to the completion of the Commercial Product Portfolio Transaction) and (ii) EVOMELA sales to a specific licensee (see Note 7 ). This amount was corrected to reflect the immaterial error identified by management as described above (see Note 13 ). ** The pre-tax gain on sale for the three months ended March 31, 2019 represents the $158.8 million gross proceeds from the Commercial Product Portfolio Transaction less our $121.2 book value of transferred net assets (inclusive of assumed liabilities) to Acrotech on the March 1, 2019 closing date less legal and banker fees aggregating $3.9 million. *** Given the immaterial error corrections identified above, there was a corresponding tax impact for the three months ended March 31, 2019. This income tax provision represents an allocation of taxes as required under intraperiod allocation guidance that was in affect at that time (see Note 9 ). This amount was corrected to reflect the immaterial error identified by management as described above (see Note 13 ). The following table presents significant non-cash items for our discontinued operations that are included as adjustments in the accompanying Condensed Consolidated Statements of Cash Flows: Three Months Ended 2020 2019 Depreciation and amortization $ — $ 1,263 Stock-based compensation $ — $ 3,405 Change in fair value of contingent consideration $ — $ 1,478

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of Stock by Class	Description of Financing Transaction No. of Common Shares Issued Proceeds Received Common shares issued pursuant to the April 2019 ATM Agreement during the year ended December 31, 2019 221,529 $ 1,814

Immaterial Restatement of Pri_2

Immaterial Restatement of Prior Period Financial Statements (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Schedule of error corrections and prior period adjustments	Condensed Consolidated Statement of Operations for the three months ended March 31, 2019: As Previously Reported Adjustments for Error Corrections As Restated Benefit for income taxes from continuing operations $ 8,242 $ (26) $ 8,216 Loss from continuing operations (39,820) (26) (39,846) Income from discontinued operations, net of income taxes ( Note 10 ) 20,665 (78) 20,587 Net loss (19,155) (104) (19,259) Condensed Consolidated Statement of Comprehensive Loss for the three months ended March 31, 2019: As Previously Reported Adjustments for Error Corrections As Restated Net loss $ (19,155) $ (104) $ (19,259) Total comprehensive loss (19,545) (104) (19,649)

Description of Business, Basi_3

Description of Business, Basis of Presentation, and Operating Segment (Details) $ in Millions	Mar. 01, 2019USD ($)product	Mar. 31, 2020Segmentproduct
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of late stage development products | product		3
Segment Reporting Information [Line Items]
Number of reportable operating segment | Segment		1
Sale | Commercial Product Portfolio
Segment Reporting Information [Line Items]
Number of products | product	7
Consideration	$ 158.8
Consideration held in escrow	4
Aggregate amount receivable based on achievement of milestones	140
Payments receivable based on achievement of regulatory milestones	40
Potential payments based on achievement of sales milestones	$ 100

Balance Sheet Account Detail -

Balance Sheet Account Detail - Summary of Cash and Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Schedule of Investments [Line Items]
Cost of equity securities	$ 6,310	$ 6,310
Foreign currency translation on equity securities	(2,789)	(2,477)
Equity securities, Unrealized Gains	16,976	27,214
Equity securities, Unrealized Losses	0	0
Equity securities (Note 7)	20,497	31,047
Cash, cash equivalents and short-term investments, amortized cost	163,692	198,309
Total cash and cash equivalents and marketable securities, Unrealized Gains	17,347	28,076
Total cash and cash equivalents and marketable securities, Unrealized Losses	(457)	(35)
Cash, cash equivalents, and short-term investments	177,793	223,873
Cash and Cash Equivalents
Schedule of Investments [Line Items]
Equity securities (Note 7)	0	0
Cash, cash equivalents, and short-term investments	70,352	64,418
Marketable Securities
Schedule of Investments [Line Items]
Equity securities (Note 7)	20,497	31,047
Cash, cash equivalents, and short-term investments	107,441	159,455
Bank deposits
Schedule of Investments [Line Items]
Available-for-sale, debt securities, amortized cost	6,070	5,219
Debt securities, available-for-sale, unrealized gain	0	0
Debt securities, available-for-sale, unrealized loss	0	0
Available-for-sale, debt securities, estimated fair value	6,070	5,219
Bank deposits | Cash and Cash Equivalents
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	6,070	5,219
Bank deposits | Marketable Securities
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	0	0
Money market funds
Schedule of Investments [Line Items]
Available-for-sale, debt securities, amortized cost	54,282	54,199
Debt securities, available-for-sale, unrealized gain	0	0
Debt securities, available-for-sale, unrealized loss	0	0
Available-for-sale, debt securities, estimated fair value	54,282	54,199
Money market funds | Cash and Cash Equivalents
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	54,282	54,199
Money market funds | Marketable Securities
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	0	0
Government-related debt securities
Schedule of Investments [Line Items]
Available-for-sale, debt securities, amortized cost	50,113	62,617
Debt securities, available-for-sale, unrealized gain	324	19
Debt securities, available-for-sale, unrealized loss	0	(10)
Available-for-sale, debt securities, estimated fair value	50,437	62,626
Government-related debt securities | Cash and Cash Equivalents
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	10,000	0
Government-related debt securities | Marketable Securities
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	40,437	62,626
Corporate debt securities
Schedule of Investments [Line Items]
Available-for-sale, debt securities, amortized cost	33,888	58,235
Debt securities, available-for-sale, unrealized gain	15	38
Debt securities, available-for-sale, unrealized loss	(159)	(25)
Available-for-sale, debt securities, estimated fair value	33,744	58,248
Corporate debt securities | Cash and Cash Equivalents
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	0	5,000
Corporate debt securities | Marketable Securities
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	33,744	53,248
Mutual funds
Schedule of Investments [Line Items]
Available-for-sale, debt securities, amortized cost	4,941	4,375
Debt securities, available-for-sale, unrealized gain	0	783
Debt securities, available-for-sale, unrealized loss	(298)	0
Available-for-sale, debt securities, estimated fair value	4,643	5,158
Mutual funds | Cash and Cash Equivalents
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	0	0
Mutual funds | Marketable Securities
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	4,643	5,158
Bank CDs
Schedule of Investments [Line Items]
Available-for-sale, debt securities, amortized cost	8,088	7,354
Debt securities, available-for-sale, unrealized gain	32	22
Debt securities, available-for-sale, unrealized loss	0	0
Available-for-sale, debt securities, estimated fair value	8,120	7,376
Bank CDs | Cash and Cash Equivalents
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	0	0
Bank CDs | Marketable Securities
Schedule of Investments [Line Items]
Available-for-sale, debt securities, estimated fair value	$ 8,120	$ 7,376

Balance Sheet Account Detail _2

Balance Sheet Account Detail - Schedule of Property and Equipment Net of Accumulated Depreciation (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$ 18,207	$ 17,619
(Less): Accumulated depreciation	(6,149)	(6,012)
Property and equipment, net of accumulated depreciation	12,058	11,607
Manufacturing equipment
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	10,815	10,355
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	3,734	3,606
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	36	36
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	3,374	3,374
Office furniture
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$ 248	$ 248

Balance Sheet Account Detail _3

Balance Sheet Account Detail - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation	$ 0.1	$ 0.1

Balance Sheet Account Detail _4

Balance Sheet Account Detail - Prepaid Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Vendor deposits	$ 9,285	$ 8,740
Prepaid insurance	978	1,408
Prepaid expenses and other assets	$ 10,263	$ 10,148

Balance Sheet Account Detail _5

Balance Sheet Account Detail - Schedule of Other Receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Insurance receivable	$ 3,337	$ 4,015
CASI other receivables	2,135	2,393
Other miscellaneous receivables	1,385	1,490
Income tax receivable - current portion	1,306	973
Interest receivable from marketable securities (see Note 3(a))	497	561
Reimbursements due from development partners for incurred research and development expenses	129	126
Other receivables	$ 8,789	$ 9,558

Balance Sheet Account Detail _6

Balance Sheet Account Detail - Summary of Other Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Key employee life insurance – cash surrender value (associated with deferred compensation plan - see Note 6)	$ 3,073	$ 3,547
Income tax receivable - non-current portion	0	334
Research & development supplies and other	114	119
Other assets	$ 3,187	$ 4,000

Balance Sheet Account Detail _7

Balance Sheet Account Detail - Facility and Equipment Under Lease (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Facility and equipment under lease	$ 3,467	$ 3,806
Office and research facilities
Lessee, Lease, Description [Line Items]
Facility and equipment under lease	3,077	3,391
Office equipment
Lessee, Lease, Description [Line Items]
Facility and equipment under lease	$ 390	$ 415

Balance Sheet Account Detail _8

Balance Sheet Account Detail - Schedule of Accounts Payable and Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Trade accounts payable and other	$ 26,937	$ 32,012
Lease liability - current portion	1,725	1,683
Accrued commercial/Medicaid rebates	2,870	2,925
Accrued product royalty due to licensors	0	66
Allowance for product returns	4,714	4,714
Accrued data and distribution fees	768	768
Accrued GPO administrative fees	6	6
Accrued inventory management fees	364	364
Allowance for government chargebacks	11,746	11,746
Accounts payable and other accrued liabilities	$ 49,130	$ 54,284

Balance Sheet Account Detail _9

Balance Sheet Account Detail - Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Commercial/Medicaid Rebates and Government Chargebacks
Accounts Payable and Other Liabilities [Roll Forward]
Beginning balance	$ 14,671	$ 22,952
Add: GTN accruals recorded for product sales	0	7,702
(Less): Payments made and credits against GTN accruals	(55)	(15,983)
Ending balance	14,616	14,671
Distribution, Data, Inventory and GPO Administrative Fees
Accounts Payable and Other Liabilities [Roll Forward]
Beginning balance	1,138	3,932
Add: GTN accruals recorded for product sales	0	1,209
(Less): Payments made and credits against GTN accruals	0	(4,003)
Ending balance	1,138	1,138
Product Return Allowances
Accounts Payable and Other Liabilities [Roll Forward]
Beginning balance	4,714	5,171
Add: GTN accruals recorded for product sales	0	167
(Less): Payments made and credits against GTN accruals	0	(624)
Ending balance	$ 4,714	$ 4,714

Balance Sheet Account Detail_10

Balance Sheet Account Detail - Summary of Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred compensation liability (Note 8(f))	$ 6,444	$ 8,597
Lease liability - non-current portion (Note 8(a))	1,981	2,372
Other tax liabilities	101	101
Other long-term liabilities	$ 8,526	$ 11,070

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 5,275,000	$ 4,595,000
SARs | Named Executive Officers
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	1,650,000
Total stock-based compensation	$ 700,000	0
us-Share-based Compensation Arrangement by Share-based Payment Award, Immediate Award Vesting Rights, Percentage	25.00%
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 3,877,000	3,626,000
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 1,398,000	$ 969,000

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Weighted average shares outstanding - basic and diluted (shares)	111,780,571	109,552,602
Net loss	$ (40,572)	$ (19,259)
Net loss per share - basic and diluted ($ per share)	$ (0.36)	$ (0.18)

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Asset and Liability Fair Values (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Assets:
Equity securities (Note 7)	$ 20,497	$ 31,047
Key employee life insurance, cash surrender value - Note 3(e))	3,073	3,547
Total Assets	174,805	222,212
Liabilities:
Deferred executive compensation liability (Note 8(f))	7,447	8,746
Total Liabilities	7,447	8,746
Government-related debt securities
Assets:
Available-for-sale	50,437	62,626
Corporate debt securities
Assets:
Available-for-sale	33,744	58,248
Money market funds
Assets:
Available-for-sale	54,282	54,199
Bank CDs
Assets:
Available-for-sale	8,120	7,376
Mutual funds
Assets:
Available-for-sale	4,652	5,169
Level 1
Assets:
Equity securities (Note 7)	20,497	31,047
Key employee life insurance, cash surrender value - Note 3(e))	0	0
Total Assets	114,833	138,040
Liabilities:
Deferred executive compensation liability (Note 8(f))	0	0
Total Liabilities	0	0
Level 1 | Government-related debt securities
Assets:
Available-for-sale	35,411	47,636
Level 1 | Corporate debt securities
Assets:
Available-for-sale	0	0
Level 1 | Money market funds
Assets:
Available-for-sale	54,282	54,199
Level 1 | Bank CDs
Assets:
Available-for-sale	0	0
Level 1 | Mutual funds
Assets:
Available-for-sale	4,643	5,158
Level 2
Assets:
Equity securities (Note 7)	0	0
Key employee life insurance, cash surrender value - Note 3(e))	3,073	3,547
Total Assets	59,972	84,172
Liabilities:
Deferred executive compensation liability (Note 8(f))	7,447	8,746
Total Liabilities	7,447	8,746
Level 2 | Government-related debt securities
Assets:
Available-for-sale	15,026	14,990
Level 2 | Corporate debt securities
Assets:
Available-for-sale	33,744	58,248
Level 2 | Money market funds
Assets:
Available-for-sale	0	0
Level 2 | Bank CDs
Assets:
Available-for-sale	8,120	7,376
Level 2 | Mutual funds
Assets:
Available-for-sale	9	11
Level 3
Assets:
Equity securities (Note 7)	0	0
Key employee life insurance, cash surrender value - Note 3(e))	0	0
Total Assets	0	0
Liabilities:
Deferred executive compensation liability (Note 8(f))	0	0
Total Liabilities	0	0
Level 3 | Government-related debt securities
Assets:
Available-for-sale	0	0
Level 3 | Corporate debt securities
Assets:
Available-for-sale	0	0
Level 3 | Money market funds
Assets:
Available-for-sale	0	0
Level 3 | Bank CDs
Assets:
Available-for-sale	0	0
Level 3 | Mutual funds
Assets:
Available-for-sale	$ 0	$ 0

Casi Holdings and Evomela Sup_2

Casi Holdings and Evomela Supply Contract - Additional Information (Details) $ in Thousands, shares in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2020USD ($)shares	Dec. 31, 2014agreement	Dec. 31, 2019USD ($)
Other Commitments [Line Items]
Equity securities	$ 20,497		$ 31,047
CASI out-license
Other Commitments [Line Items]
Number of agreements | agreement		3
Number of shares held in investment (shares) | shares	10
Percentage of ownership	10.00%
Equity securities	$ 20,500

Financial Commitments & Conti_3

Financial Commitments & Contingencies and Key License Agreements - Additional Information (Details) $ in Thousands	1 Months Ended			3 Months Ended
	Apr. 30, 2019USD ($)	Apr. 30, 2018USD ($)	Apr. 30, 2016shares	Mar. 31, 2020USD ($)product	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Jan. 01, 2019USD ($)
Long-term Purchase Commitment [Line Items]
Lease cost				$ 595	$ 583
Operating lease right-of-use assets - non-current				3,467		$ 3,806
Right-of-use asset obtained in exchange for operating lease liability				5,300	$ 4,200
Operating lease liability				$ 3,706		4,055
Licensors | product				2
Deferrals and contributions				$ 7,400		$ 8,700
ImmunGene
Long-term Purchase Commitment [Line Items]
Potential payments based on achievement of regulatory milestones				26,100
Asset purchase agreement, upfront payment	$ 2,800
Potential payments based on additional achievements of regulatory milestones				5,000
MD Anderson
Long-term Purchase Commitment [Line Items]
Potential payments based on achievement of regulatory milestones				6,000
Potential payments based on achievement of sales milestones				24,000
Payment Of Upfront Fee		$ 500
SPI-2012
Long-term Purchase Commitment [Line Items]
Issuance (shares) | shares			318,750
Potential payments based on achievement of regulatory milestones				10,000
Potential payments based on achievement of sales milestones				120,000
Poziotinib | Licensing Agreements
Long-term Purchase Commitment [Line Items]
Potential payments based on achievement of regulatory milestones				33,000
Potential payments based on achievement of sales milestones				$ 325,000
ASU 2016-02
Long-term Purchase Commitment [Line Items]
Operating lease right-of-use assets - non-current							$ 4,200
Operating lease liability							$ 4,200
Minimum
Long-term Purchase Commitment [Line Items]
Remaining lease term				1 year
Maximum
Long-term Purchase Commitment [Line Items]
Remaining lease term				4 years

Financial Commitments & Conti_4

Financial Commitments & Contingencies and Key License Agreements - Operating Lease Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use assets - non-current	$ 3,467	$ 3,806
Operating lease liabilities - current	1,725	1,683
Operating lease liabilities - non-current	1,981	2,372
Total operating lease liabilities	$ 3,706	$ 4,055

Financial Commitments & Conti_5

Financial Commitments & Contingencies and Key License Agreements - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 466	$ 459
Variable lease cost	114	108
Short-term lease cost	15	15
Total lease cost	$ 595	$ 583

Financial Commitments & Conti_6

Financial Commitments & Contingencies and Key License Agreements - Summary of Operating Lease Term and Discount Rate (Details)	Mar. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Weighted Average Remaining Lease Term	2 years 2 months 12 days	2 years 6 months
Weighted Average Discount Rate	7.80%	7.80%

Financial Commitments & Conti_7

Financial Commitments & Contingencies and Key License Agreements - Contractual Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
2020 (remaining)	$ 1,458
2021	1,671
2022	828
2023	87
2024	0
Total future lease payments, undiscounted	4,044
(Less): Implied interest	(338)
Present value of operating lease payments	$ 3,706	$ 4,055

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Benefit for income taxes from continuing operations	$ 0	$ 8,216
Income tax expense from discontinued operations		6,700
Income tax benefit from continuing and discontinued operations		$ 1,500

Discontinued Operations - Conde

Discontinued Operations - Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	Mar. 01, 2019	Mar. 31, 2020	Mar. 31, 2019
Other (expense) income:
Provision for income taxes from discontinued operations			$ (6,700)
Income from discontinued operations, net of income taxes		$ 45	20,587
Sale | Commercial Product Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues		(220)	14,369
Operating costs and expenses:
Cost of sales (excluding amortization of intangible assets)		(229)	3,168
Selling, general and administrative		(1)	5,951
Research and development		(35)	2,536
Amortization of intangible assets		0	1,248
Restructuring charges - employee severance (Note 11)		0	6,297
Total operating costs and expenses		(265)	19,200
Income (loss) from discontinued operations		45	(4,831)
Other (expense) income:
Change in fair value of contingent consideration		0	(1,478)
Gain on sale of Commercial Product Portfolio**		0	33,644
Total other (expense) income		0	32,166
Income from discontinued operations before income taxes		45	27,335
Provision for income taxes from discontinued operations		0	(6,748)
Income from discontinued operations, net of income taxes		45	20,587
Proceeds from sale of discontinued operations	$ 158,800
Carrying value of net assets transferred	121,200
Transaction expenses	$ 3,900
Sale | Commercial Product Portfolio | Product
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues		(220)	14,079
Sale | Commercial Product Portfolio | License fees and service revenue
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenues		$ 0	$ 290

Discontinued Operations - Signi

Discontinued Operations - Significant Non-cash Supplemental Cash Flow Items of Discontinued Operations (Details) - Commercial Product Portfolio - Sale - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization	$ 0	$ 1,263
Stock-based compensation	0	3,405
Change in fair value of contingent consideration	$ 0	$ 1,478

Restructuring Costs Related T_2

Restructuring Costs Related To Sale Of Commercial Product Portfolio (Details) $ in Thousands	Mar. 01, 2019employee	Mar. 31, 2020USD ($)	May 31, 2019USD ($)	Mar. 31, 2019USD ($)
Restructuring Cost and Reserve [Line Items]
Number of employees terminated or given notice of termination | employee	87
Revenue from contract with customer		$ 0		$ 0
Employee severance
Restructuring Cost and Reserve [Line Items]
Restructuring costs expected cost remaining		$ 200		1,100
Employees terminated March 1, 2019 | Employee severance
Restructuring Cost and Reserve [Line Items]
Restructuring costs				8,300
Employees terminated March 1, 2019 | Employee severance | Income from discontinued operations, net of income taxes
Restructuring Cost and Reserve [Line Items]
Restructuring costs				6,300
Employees terminated March 1, 2019 | Employee severance | Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs				1,500
Employees terminated March 1, 2019 | Employee severance | Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring costs				500
Employees given notice of May 31, 2019 | Employee severance
Restructuring Cost and Reserve [Line Items]
Restructuring costs			$ 500	200
Acrotech | Service [Member]
Restructuring Cost and Reserve [Line Items]
Revenue from contract with customer				$ 200

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Apr. 30, 2019	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2020
Equity [Abstract]
Maximum proceeds	$ 75,000,000
Proceeds Received (Net of Broker Commissions and Fees )		$ 0	$ 1,814,000	$ 1,800,000
Common stock issued (shares)			221,529

Immaterial Restatement of Pri_3

Immaterial Restatement of Prior Period Financial Statements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes	$ 0	$ (8,216)
Loss from continuing operations	(40,617)	(39,846)
Income from discontinued operations, net of income taxes (Note 10)	45	20,587
Net loss	(40,572)	(19,259)
Total comprehensive loss	(41,901)	(19,649)
Accumulated deficit	$ (764,999)		$ (724,427)	$ (611,738)
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes		(8,242)
Loss from continuing operations		(39,820)
Income from discontinued operations, net of income taxes (Note 10)		20,665
Net loss		(19,155)
Total comprehensive loss		(19,545)
Accumulated deficit				$ 599,886
Adjustments for Error Corrections
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision (benefit) for income taxes		26
Loss from continuing operations		(26)
Income from discontinued operations, net of income taxes (Note 10)		(78)
Net loss		(104)
Total comprehensive loss		(104)
Pricing Of ZEVALIN to qualifying public health services | Adjustments for Error Corrections
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Error correction amount		$ 12,000